Introduction {#s1}
============

Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in [@bib42]; [@bib58]). In homozygous loss-of-function *adgrg6* zebrafish and mouse mutants, peripheral myelination is severely impaired: Schwann cells associate with axons, but are unable to generate the myelin sheath, and show reduced expression of the *myelin basic protein* (*mbp*) gene ([@bib23]; [@bib49]; [@bib50]; [@bib51]). Targeted disruption of *Adgrg6* in the mouse results in additional abnormal phenotypes, including limb and cardiac abnormalities, axon degeneration and embryonic lethality ([@bib51]; [@bib57]; [@bib86]). In humans, mutations in *ADGRG6* are causative for congenital contracture syndrome 9, a severe type of arthrogryposis multiplex congenita ([@bib65]). Peripheral nerves from affected individuals have reduced expression of myelin basic protein, suggesting that the function of ADGRG6 in myelination is evolutionarily conserved from teleosts to humans ([@bib65]). Human *ADGRG6* variants have also been proposed to underlie some paediatric musculoskeletal disorders, including adolescent idiopathic scoliosis ([@bib39]) (and references within).

In zebrafish, homozygous loss-of-function *adgrg6* mutants exhibit an inner ear defect in addition to deficiencies in myelination ([@bib21]; [@bib50]). In the otic vesicle, the epithelial projections that prefigure formation of the semicircular canal ducts overgrow and fail to fuse, resulting in morphological defects and ear swelling. Analysis of the zebrafish *adgrg6* mutant ear shows a dramatic alteration in the expression of genes coding for several extracellular matrix (ECM) components and ECM-modifying enzymes ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). Notably, transcripts coding for core proteins of the chondroitin sulphate proteoglycan Versican, normally transiently expressed in the outgrowing projections and then down-regulated once projection fusion has occurred, remain highly expressed in the overgrown and unfused projections of *adgrg6* mutants ([@bib21]). Although *Adgrg6* (*Gpr126*) mRNA is known to be expressed in the mouse ear ([@bib57]), a role in otic development in the mammal has yet to be determined.

![Comparison of *adgrg6* mutant allele phenotypes in the inner ear and peripheral nervous system.\
(**A**) (i--iii) Live images of 4 dpf otic vesicles, lateral view. (i) Wild-type sibling, (ii) *adgrg6^tb233c^*, (iii) *adgrg6^fr24^* showing the swollen, unfused projections in the homozygous mutant otic vesicles in ii and iii compared with the fused pillars in the wild-type ear (marked with dotted lines). (iv--vi) ISH with *vcanb* at 4 dpf. (iv) Wild-type sibling, (v) *adgrg6^tb233c^*, (vi) *adgrg6^fr24^* mutant ears showing overexpression of *vcanb* in the unfused projections. Stronger staining is seen in the stronger allele, *fr24*. (vii--xi) ISH with *mbp* at 4 dpf, (vii-ix) dorsal views, (x--xii) lateral views. (vii, x) wild-type sibling, (viii, xi) *adgrg6^tb233c^*, (ix, xii) *adgrg6^fr24^* showing complex staining patterns in the PNS (black arrows and arrowheads) and CNS (white arrowheads). *mbp* staining around the PLLg is absent in both *tb233c* and *fr24* alleles (black arrowheads); staining in the posterior lateral line nerve is variable in *tb233c* mutants and absent in *fr24* mutants (black arrows). (**B**) Schematic diagram showing the structure of the Adgrg6 receptor and the positions of the predicted amino acid changes for the two *adgrg6* mutant alleles used in this study. (**C**) Light-sheet microscope images using a transgenic line expressing GFP in the otic epithelium, showing a dorsal view of the ear (anterior to the top). (i--iii) Wild-type sibling showing anterior and posterior pillars formed from fused projections (iii). Note that images are flipped horizontally from the originals for ease of comparison (see [Video 1](#video1){ref-type="video"}; t0 on the stills corresponds to \~100 mins into the video). (iv--vi) Still images from a time-lapse video of *adgrg6^fr24^* mutant with unfused projections that roll around each other (see [Video 2](#video2){ref-type="video"}). Abbreviations: AC, lumen of anterior semicircular canal; ap, anterior projection; CTF, carboxy-terminal fragment; CUB, Complement C1r/C1s, Uegf, BMP1 domain; ECD, extracellular domain; GAIN, GPCR auto-proteolysis domain; GPS, GPCR proteolytic site; HBD, hormone binding domain; ICD, intracellular domain; NTF, amino-terminal fragment; PC, lumen of posterior semicircular canal; pp, posterior projection; PTX, Pentraxin domain; vp, ventral projection; 7TM, 7-transmembrane domain. Scale bars: 50 μm in Ai, for Aii--vi; 100 μm in Avii, for Aviii--xii; 20 μm in Ci, for Cii--vi.](elife-44889-fig1){#fig1}

Like all aGPCR members, the zebrafish Adgrg6 receptor consists of a long extracellular domain (ECD), a seven-pass transmembrane domain (7TM), and a short intracellular domain (reviewed in [@bib42]) ([Figure 1B](#fig1){ref-type="fig"}). The ECD includes a GPCR autoproteolysis-inducing (GAIN) domain, which incorporates the GPCR proteolytic site (GPS) and the conserved Stachel sequence ([@bib43]; [@bib58]). Proteolysis at the GPS results in two fragments, an N-terminal fragment (NTF) and a C-terminal fragment (CTF), which can remain associated with one another, or may dissociate, the NTF binding to cell surface or extracellular matrix ligands ([@bib58]; [@bib61]). Dissociation of the NTF triggers binding of the Stachel sequence to the 7TM domain, thereby activating the CTF ([@bib43]). This feature provides a variety of CTF-dependent or -independent signalling capabilities that orchestrate cell adhesion and other cell-cell or cell-matrix interactions. For example, during Schwann cell development and terminal differentiation, the Adgrg6 NTF promotes radial sorting of axons, whereas the CTF is thought to signal through a stimulatory Gα subunit (Gα~s~), leading to elevated cAMP levels and activated protein kinase A (PKA) to induce transcription of downstream target genes, such as *egr2* and *oct6* ([@bib61]). Compounds that act to raise intracellular cAMP levels, such as the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the adenylyl cyclase activator forskolin, can rescue phenotypic defects in both the inner ear and PNS in *adgrg6* mutants ([@bib21]; [@bib50]).

Despite the enormous importance of GPCRs as drug targets ([@bib26]; [@bib77]; [@bib94]), adhesion class GPCRs remain poorly characterised, representing a valuable untapped resource as targets of future therapeutics ([@bib25]; [@bib52]). The identification of specific modulators of aGPCR activity is an essential step for understanding the mechanism of aGPCR function and to inform the design of new drugs. Recent successful approaches include the use of Stachel sequence peptides as aGPCR agonists ([@bib18]), or synthetic monobodies directed against domains within the NTF ([@bib71]). A promising alternative approach lies in the potential of unbiased whole-animal screening of small molecules. In recent years, zebrafish have emerged as an important tool for in vivo phenotypic screening for new therapeutics ([@bib10]) and for understanding biological mechanisms ([@bib6]; [@bib68]). Zebrafish have many advantages for drug discovery: they are a vertebrate species whose embryos can fit into individual wells of a multiwell plate, facilitating high-throughput analysis; they generate large numbers of offspring; they can absorb compounds directly added to the water, and whole-organism screening enables toxicity, absorption, metabolism and excretion of compounds to be assayed early in the screening pipeline.

To date, over one hundred drug screens using different zebrafish disease models have been conducted, some identifying lead compounds that have subsequently been tested in mammalian model systems or entered clinical trials ([@bib17]; [@bib24]; [@bib54]; [@bib55]) (reviewed in [@bib6]). Two screens have been performed to identify compounds that promote myelination in the central nervous system ([@bib15]; [@bib19]). These studies used live imaging of *Tg(olig2:GFP)* or *Tg(mbp:eGFP)* fluorescent transgenic lines to screen for small molecules that increase progenitor or myelinating oligodendrocyte cell number. While elegant in design, and successful in identifying hit compounds, these screens required the use of sophisticated and costly high-resolution imaging platforms and relied on detailed quantitative assays for cell number, techniques that are not available to all labs and are potentially limiting in scalability and throughput.

In this study, we have developed an in vivo drug screening assay based on semi-automated in situ hybridisation (ISH) to identify modulators of the Adgrg6 pathway. We have used the otic expression of *versican b (vcanb)* as an easily-scored qualitative readout to identify compounds that can reduce *vcanb* overexpression back to normal levels in a hypomorphic mutant allele for *adgrg6*, *tb233c*. We used expression of *mbp* in the posterior lateral line ganglion of *adgrg6^tb233c^* mutants as a secondary screening assay, with the aim of identifying chemical classes capable of rescuing the expression of both genes, which may thus represent agonists of the Adgrg6 signalling pathway. To identify ligands that potentially bind directly to Adgrg6, we then tested hit compounds for their ability to rescue a strong loss-of-function *adgrg6* allele, *fr24*, which predicts a severely truncated protein. Several compounds were unable to rescue *adgrg6^fr24^* mutants, including a group with similar structures from the gedunin family of compounds. Compounds able to rescue both alleles include colforsin, a known activator of adenylyl cyclase, demonstrating proof-of-principle that our screen can identify compounds that restore GPCR pathway activity downstream of the receptor. These alternative assays for both down-regulation and up-regulation of gene expression, combined with a comparison of rescue in both weak and strong alleles, have facilitated selection of a strong cohort of hit compounds that can be differentiated by the different screens used. Our approach is scalable and can be used to screen additional compound collections. In parallel, chemoinformatics analysis of the compound libraries and identified hits has enabled classification and prioritisation of selected hit compounds.

Results {#s2}
=======

Choice of markers for an in situ hybridisation-based screen: otic *vcanb* expression as a robust readout {#s2-1}
--------------------------------------------------------------------------------------------------------

We set out to develop a simple assay to identify small molecule modifiers of the Adgrg6 pathway that can be used both to understand Adgrg6 function and to identify compounds that could inform the design of therapeutics. To this end, we chose to perform a drug screen based on in situ hybridisation (ISH), which has the advantage of being a simple, reproducible assay that can be semi-automated ([@bib5]; [@bib54]). We selected *vcanb* expression in the *adgrg6* mutant ear for our primary screen. *vcanb* has a number of advantages for screening, including highly localised expression in the otic vesicle, very strong and reproducible staining intensity in *adgrg6* mutant embryos, and a clear difference between staining in mutant and wild-type embryos at the stage chosen, making it ideal for manual scoring ([Figure 1A](#fig1){ref-type="fig"}). We therefore developed a primary screen seeking compounds that can reduce *vcanb* levels in *adgrg6* mutant embryos and rescue the mutant phenotype. We reasoned that, in addition to yielding information for the ear phenotype, compounds that can rescue *vcanb* expression may also rescue myelination defects in the PNS, where expression patterns of genetic markers are more complex and defects are harder to score.

We first made a careful comparison of the otic and PNS defects in weak (*tb233c*) and strong (*fr24*) alleles for the *adgrg6* mutant ([Figure 1A](#fig1){ref-type="fig"}). The *tb233c* allele is a missense mutation (I963N) in the fourth transmembrane domain of the receptor, whereas the *fr24* allele is a nonsense mutation (L463X), predicting a severely truncated protein lacking the hormone-binding, GAIN, 7TM and C-terminal domains ([@bib21]) ([Figure 1B](#fig1){ref-type="fig"}). Mutants for both *tb233c* and *fr24* alleles have the same defect in semicircular canal formation: otic epithelial projections are enlarged, overgrow, and fail to fuse to form the three pillars that create the hubs of the semicircular canal ducts ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). Time-lapse imaging using light-sheet microscopy reveals the dynamics of this process: even when projections make contact with each other, they fail to adhere as in the wild type. Instead, projections in the mutant ear continue to grow, roll around one another as they find space with least resistance, and fill the otic vesicle with semicircular canal projection tissue ([Figure 1C](#fig1){ref-type="fig"}; [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). In wild-type ears, *vcanb* is expressed in the growing semicircular canal projections between 44 and 72 hr post fertilisation (hpf), but is then strongly down-regulated after fusion; by 4 days post fertilisation (dpf), very little expression is detectable in the ear ([@bib21]). By contrast, in *adgrg6* mutants, the overgrown and unfused projections in the developing ear continue to express *vcanb* at high levels ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). Both alleles show a dramatically increased level of expression over wild-type embryos, but the increase is stronger in the *fr24* allele ([Figure 1A](#fig1){ref-type="fig"}). mRNA for *adgrg6* itself is expressed in the otic vesicle of mutant embryos for both alleles ([@bib21]) (and unpublished data), but it is not known whether a truncated protein including the CUB and PTX domains is produced in the *fr24* allele. (Note, however, that some biological activity is retained for a different truncating mutation, Y782X, in the Adgrg6 NTF \[[@bib61]\]).

###### Light-sheet microscope time-lapse video of the ear shown in [Figure 1Ci-iii](#fig1){ref-type="fig"}.

Dorsal view (anterior to top) of the left inner ear of a phenotypically wild-type sibling embryo showing the anterior, lateral and posterior projections (the anterior projection is partially out of view). In the video, the posterior projection grows and meets the posterior bulge from the lateral projection. The projection and bulge meet, fuse and resolve to form a pillar over 900 min (approximately 55 hpf--70 hpf). The video shows a Maximum Intensity Projection of selected *z*-slices spanning approximately 6 µm, captured every 10 min, and played back at 10 frames per second. Selected stills from the video, flipped horizontally to match the panels showing the mutant ear, are shown in [Figure 1C](#fig1){ref-type="fig"}.

10.7554/eLife.44889.005

###### Light-sheet microscope time-lapse video of the ear shown in [Figure 1Civ-vi](#fig1){ref-type="fig"}.

Dorsal view of the right inner ear of an *adgrg6^fr24^* mutant embryo showing anterior, lateral and posterior projections (the posterior projection is partially out of view). In the video, the anterior projection and anterior bulge from the lateral projection touch, but continue to grow past one another. The unfused projections roll around each other over 900 min (approximately 60 hpf--75 hpf). The video shows a Maximum Intensity Projection of selected *z*-slices spanning approximately 20 µm, captured every 5 min, and played back at 20 frames per second. Selected stills from the video are shown in [Figure 1C](#fig1){ref-type="fig"}.

10.7554/eLife.44889.006

In addition to an upregulation of *vcanb* expression in the ear, the zebrafish *adgrg6* mutant also shows a reduction or loss of expression of the *myelin basic protein* (*mbp*) gene in the PNS ([@bib21]; [@bib50]). This additional phenotype proved to be very valuable for our screen design, helping to validate hits and eliminate false positives. Expression of *mbp* is present in a complex pattern in wild-type embryos, and shows clear differences between the two alleles, correlating with the predicted severity of the mutations ([Figure 1B](#fig1){ref-type="fig"}). Expression is variably reduced along the posterior (trunk) lateral line nerve in homozygous mutants for the hypomorphic *tb233c* allele, but in all individuals there is consistent absence of staining in cells (presumed Schwann cells) associated with the posterior lateral line ganglion (PLLg) ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The *fr24* allele lacks nearly all *mbp* staining along peripheral nerves ([@bib21]) ([Figure 1A](#fig1){ref-type="fig"}). Note that expression of *mbp* in the central nervous system (CNS) is not affected in either allele, obscuring any reduction of *mbp* staining in the PNS without performing a detailed analysis. This made *mbp* expression unsuitable for a primary screen, but useful for a secondary screen of hit compounds identified from the *vcanb* screen.

Design of a screening pipeline for compounds that rescue the *adgrg6^tb233c^* mutant phenotype {#s2-2}
----------------------------------------------------------------------------------------------

Our strategy for the screening protocol and analysis pipeline is outlined in [Figure 2](#fig2){ref-type="fig"}. Both the weak (*tb233c*) and strong (*fr24*) alleles of *adgrg6* mutants are homozygous viable, enabling large batches of 100% mutant embryos to be generated for each assay. We decided to use the hypomorphic allele (*tb233c*) in our primary screen, for four main reasons: (1) adult fish homozygous for the *tb233c* allele produce a larger number of healthy embryos than adults homozygous for the *fr24* allele; (2) a lower concentration of our positive control compound IBMX was sufficient to rescue the phenotype in *tb233c* mutants compared with *fr24* mutants ([@bib21]), suggesting that the *tb233c* allele might also be easier to rescue with other compounds in the libraries screened; (3) *vcanb* expression, although not as dramatically affected as in *fr24*, is still robustly over-expressed in the *tb233c* allele, and (4) we predicted that any small molecules that interact with the active site of the receptor or act as allosteric modulators would be missed in a screen using *fr24* mutants, which should only be able to identify compounds acting on targets downstream of the receptor. By using *tb233c*, we should be able to identify modulators of the pathway acting both downstream and at the level of the receptor itself.

![Overview of the screening assay protocol and strategy.\
(**A**) Schematic of the screening assay protocol. Homozygous adult *adgrg6^tb233c^* mutant fish were paired to raise large numbers of *adgrg6^tb233c^* mutant embryos. Embryos were grown until 60 hpf, when the lateral, anterior and posterior epithelial projections in the inner ear are evident. Three embryos were aliquoted into each well of a mesh-bottomed multiwell plate in E3 medium. The mesh-bottomed plate was then transferred to the drug plate containing control compounds as shown in the plate layout and library compounds at 25 µM in 250 µL of E3 embryo medium. Plates were incubated at 28°C until 90 hpf. The mesh-bottomed plate and embryos were then transferred to 4% PFA for fixation (4°C, overnight) and then processed for ISH to *vcanb*. Micrographs show a selection of typical results. Treatment with 100 µM IBMX (positive control, top) results in loss (rescue) of otic *vcanb* expression (white arrowhead). Strong otic *vcanb* expression (black arrowhead) is evident in embryos where the compound had no effect (non-hit) and in negative control wells (not shown). Note the spot of stain in each embryo, marking expression in the otic vesicle. Three examples are shown of wells where compounds were scored as a hit; one of these (Hit 2) was IBMX, represented in the Spectrum collection. (**B**). Pipeline of the compound screening strategy and chemoinformatics analysis. The left hand side describes the flow of experimental work and the right hand side describes the complementary chemoinformatics processes. For details, see the text.](elife-44889-fig2){#fig2}

Choice of controls {#s2-3}
------------------

In all assay plates, we included the phosphodiesterase inhibitor IBMX (100 µM) as a positive control. We have previously shown that addition of 100 μM IBMX at 60 hpf is optimal for both down-regulation of *vcanb* expression and a rescue of projection fusion in the ears of *adgrg6^tb233c^* mutants ([@bib21]). At this stage of development, the anterior and posterior projections in the mutant otic vesicle are extended and in close proximity to the lateral projection, to which they would fuse in the wild type ([Figure 2A](#fig2){ref-type="fig"}). Compounds from both libraries are supplied as stocks dissolved in DMSO; we therefore used 1% DMSO as a negative control. The *nacre* (*mitfa^-/-^*) strain, which has reduced pigmentation, facilitating visualisation of ISH staining patterns, was used as an untreated wild-type control. Three embryos per well were treated with compounds at 25 µM in E3 medium from 60 to 90 hpf, after which they were fixed and analysed for expression of *vcanb* by whole-mount ISH. At the embryonic stage assayed by ISH (90 hpf), expression of *vcanb* in untreated mutant embryos is very specific to the ear, making it clearly visible as two dark spots in the head of each embryo within the well. All controls gave results as expected in all assay plates tested: DMSO-treated mutant embryos showed strong otic staining for *vcanb*, untreated wild-type embryos showed very little staining in the ear, and IBMX-treated mutant embryos showed rescued (down-regulated) otic *vcanb* expression ([Figure 2A](#fig2){ref-type="fig"}).

Comparison of compound libraries with diverse structures {#s2-4}
--------------------------------------------------------

In order to test a wide range of compounds, we chose to screen two commercially available small molecule libraries. The Tocriscreen Total library ('Tocris') consists of 1120 compounds representing known bioactive compounds with diverse structures. The Spectrum Collection ('Spectrum'; Microsource Discovery Systems) comprises 2000 compounds, including FDA-approved drugs for repurposing, bioactive compounds and natural products. Scaffold analysis of the two libraries highlights the structural diversity present ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Based on Bemis-Murcko scaffolds ([@bib8]), the Tocris library of 1120 compounds has 693 (62%) scaffolds representing a single compound and only two scaffolds representing more than 10 compounds. The Spectrum library has 682 scaffolds representing unique chemical structures, but as the library consists of 2000 compounds, the proportion of scaffolds represented by a single molecule (30%) is lower than for the Tocris library. Together, the two libraries cover a wide range of chemical space, with a total of 1540 scaffolds, of which 1134 represent unique compounds. Scaffold analysis not only provides a broad overview of the chemical diversity of each library, but can also be used to select and analyse groups of similar compounds with interesting structure-activity relationships. Compounds were also clustered based on their fingerprint similarity using Ward's method of hierarchical agglomerative clustering, which was useful for visualisation purposes (for dendrograms, see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Results of the primary screen for reduction of otic *vcanb* expression levels {#s2-5}
-----------------------------------------------------------------------------

To score the efficacy of the compounds in down-regulating *vcanb* mRNA levels, we used a scoring system from 0 to 3 ([Figure 3](#fig3){ref-type="fig"}; for details, see the Materials and methods). In the primary screen, each compound was tested against three embryos and the score for each embryo was added to give a final score out of 9. The final scores were classified into different groups according to the thresholds shown in [Figure 3B](#fig3){ref-type="fig"}, with the highest degree of rescue in Category A, representing a combined score no greater than 2. Completion of the primary *vcanb* screen for all 3120 compounds identified 92 (8%) compounds from the Tocris library and 205 (10%) from the Spectrum library that scored in categories A--C ([Figure 3C,E](#fig3){ref-type="fig"}). 5% of the compounds from each library were found to be either toxic (category F; dead embryos or severe developmental abnormalities) or potentially corrosive (category G; no embryos present), whereas 99 (9%) compounds from Tocris and 269 (13%) from Spectrum were found to cause incomplete or partial suppression of *vcanb* expression (category D). The largest category (E; 2282 compounds from both libraries, 73%), as expected, represented compounds that had no rescuing or other effect at the concentration used (25 µM). To visualise the complete set of screening results and to identify any clusters of hit compounds with similar structures, compounds were displayed as individual data points on a polar scatterplot ([Figure 3D,F](#fig3){ref-type="fig"}; [Figure 4](#fig4){ref-type="fig"}; interactive version at <https://adlvdl.github.io/visualizations/polar_scatterplot_whitfield_vcanb.html>). Compound position along the circumference of the plot for each library is based on position on the respective similarity dendrogram ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Data points that are clustered along radii of the plot are thus more likely to be structurally similar, although note that the juxtaposition of different branches of the dendrogram can also place compounds that differ in structure adjacent to one other. Due to the wide diversity of scaffolds found in the Tocris library, less clustering of hit compounds (A--C) can be observed compared with the molecules in the Spectrum library, where more clusters of compounds in the A--C categories are evident ([Figure 3D,F](#fig3){ref-type="fig"}).

![A primary drug screen identified 92 (Tocris) and 205 (Spectrum) putative hit compounds able to down-regulate *vcanb* mRNA expression in *adgrg6^tb233c^* mutants.\
(**A**) Scoring system used to assess *vcanb* mRNA expression levels in the inner ear of *adgrg6^tb233c^* embryos after treatment. (Ai) *vcanb* mRNA expression in the untreated/DMSO-treated *adgrg6^tb233c^* mutant ear (score 3). Scores 2 (Aii) and 1 (Aiii) were given to embryos that showed reduced *vcanb* mRNA expression to some extent, with 1 given for a stronger down-regulation than 2. (Aiv) Score 0 was given to embryos where *vcanb* mRNA levels were equivalent to wild-type levels. (**B**) Compounds were categorised A--G according to the total *vcanb* score from the three embryos treated. Colours for each category correspond to the colours used in panels C--F. (**C, E**) Pie charts showing the distribution of compounds from the Tocris (**C**) and Spectrum (**E**) libraries in categories A--G. (**D, F**) Compounds from the Tocris and Spectrum libraries were ordered according to similarities in their chemical structure and presented as individual dots in polar scatterplots in D and F, respectively, with jitter (noise) introduced to improve visualisation. The Spectrum library results have a higher level of clustering as expected from the scaffold analyses. Scale bar: 50 μm.\
10.7554/eLife.44889.011Figure 3---source data 1.Source data for [Figure 3D](#fig3){ref-type="fig"}.Dendrogram representing structural similarity between library compounds (Tocris). Dendrogram of the Tocriscreen Total library compounds based on the similarity matrix between all pairs of compounds (Ward's method of hierarchical agglomerative clustering---see Materials and methods). Compounds are named by their plate and well ID.\
10.7554/eLife.44889.012Figure 3---source data 2.Source data for [Figure 3F](#fig3){ref-type="fig"}.Dendrogram representing structural similarity between library compounds (Spectrum). Dendrogram of the Spectrum library compounds based on the similarity matrix between all pairs of compounds. Compounds are named by their plate and well ID.](elife-44889-fig3){#fig3}

![Retesting and counter screen for *mbp* expression reveals chemical clustering of hit compounds.\
(**A**) Scoring system used to assess *mbp* mRNA expression levels around the PLLg of *adgrg6^tb233c^* embryos after treatment. (Ai) A score of 3 was given to embryos where *mbp* mRNA expression was similar to wild-type levels. Black arrowhead: *mbp* expression around the PLLg. (Aii) A score of 2 was given to embryos that showed weak *mbp* expression around the PLLg. (Aiii) A score of 1 was given to embryos with *mbp* expression identical to that in untreated *adgrg6^tb233c^* mutants (absence of *mbp* expression around the PLLg (white arrowhead), with weak expression elsewhere). (Aiv) A score of 0 was used to indicate embryos where *mbp* mRNA expression was absent throughout the PNS. Asterisks mark expression near the three cristae of the ear. Scale bar: 50 μm. (**B, C**) *mbp* scoring system and classification of the compounds. (**B**) Compounds were categorised according to the *mbp* score sum from three embryos (average from two experiments; six embryos total) and grouped into compounds able to rescue *mbp* expression (score \>3.5--9) and unable to rescue *mbp* expression (\>1.5--3.5). A third class of compounds down-regulated both *vcanb* and *mbp* (score 0--1.5) and were not followed further. (**C**) Distribution of the compounds in the different rescue categories after the *mbp* counter screen. (**D**) Compounds from both libraries are represented as individual dots in a combined polar scatterplot (3120 compounds in total; <https://adlvdl.github.io/visualizations/polar_scatterplot_whitfield_vcanb.html>). Compounds were ordered according to similarities in their chemical structure and placed in concentric circles according to the category A--G they were assigned to after the primary screen, with jitter (noise) introduced to improve visualisation. (**E**) Polar scatter plot of the 91 hit compounds that passed the first retest and were followed up with *mbp* counter screens; previous scores for the compounds not followed are faded. (**F**) Polar scatter plot of the final 68 hit compounds (non-faded) after *mbp* counter screens. Bigger dots represent compounds that rescued *mbp* expression, whereas smaller dots correspond to the compounds that did not rescue *mbp* expression; compounds that downregulated *mbp* expression, or were not followed, are faded. Wedges on the scatter plot delineate the two clusters of compounds with similar structures for which some hits were followed up in further analysis (see text). The positions of IBMX (I) and colforsin (C) are indicated (red arrowheads). (**G**) Overview of the hit selection process. The length of the horizontal bars is proportional to the number of hit compounds taken through to each stage. Data for the Tocris library are on the left-hand side; data for the Spectrum library are on the right-hand side. The proportion of compounds in hit categories A, B and C are shown using the same colour scheme as in [Figure 3](#fig3){ref-type="fig"}, with the top bar representing the number of hits from the primary screen listed in [Figure 3B](#fig3){ref-type="fig"}. The second bar shows the number of compounds that were cherry-picked. The average scores from nine embryos (after retests) is shown in the third bar. Note that some compounds will change category after the retests and the number of category C compounds is increased. Any compounds that failed to rescue in any single retest were also not taken forward (fourth bar). The *mbp* data (**E**) are represented in the fifth and sixth bars. The final bar represents the compounds that were unable to rescue the strong *fr24* allele. The total number of compounds at each stage is shown in the centre. Asterisks denote numbers that do not include duplicate compounds.\
10.7554/eLife.44889.014Figure 4---source data 1.Source data for [Figure 4D](#fig4){ref-type="fig"}.Dendrogram representing structural similarity between library compounds (Combined). Dendrogram of the combined Spectrum and Tocriscreen Total library compounds based on the similarity matrix between all pairs of compounds. Compounds are named by their plate and well ID.](elife-44889-fig4){#fig4}

Validation of the primary screen: retesting, comparison with control compounds and analysis of duplicates {#s2-6}
---------------------------------------------------------------------------------------------------------

Possible hit compounds categorised as A--C were selected and arrayed into cherry-pick plates, which were tested using the same assay format. These included all the top hit compounds that scored A or B, and a selection of compounds from the lower-scoring C category (see Materials and methods). Specifically, 83 out of the 92 possible hit compounds from the Tocris library and 145 of the 205 possible hits from the Spectrum library were retested twice, again with three embryos per well. By increasing the number of embryos screened to a total of nine per compound, we aimed to eliminate any false-positive hits that had an increased average score over these two retests or did not show a clear rescue (score \>7) in any individual test. In total, 91 compounds from the combined list of hits (29 from Tocris, 62 from Spectrum) that showed consistent rescue of *vcanb* expression across the retests were taken forward for secondary assays ([Figure 4G](#fig4){ref-type="fig"}).

To provide further validation for the hits identified in the primary screen, we used two approaches. Firstly, we compared the results of our control compounds to those of similar compounds present in the screened compound libraries. The control compound IBMX, a non-selective phosphodiesterase (PDE) inhibitor, is present in the Spectrum library and was identified as a hit in the primary screen ([Figure 2A](#fig2){ref-type="fig"}). The most similar compound to IBMX from both libraries is 8-methoxymethyl-3-isobutyl-1-methylxanthine (MMPX), a selective PDE-1 inhibitor. MMPX is present in the Tocris library, but was not identified as a hit in our screen, most likely due to its selectivity. In previous work we also used forskolin to raise cAMP levels and rescue the *adgrg6* ear phenotype ([@bib21]), but forskolin requires different assay conditions with short drug incubation times to avoid toxicity. Forskolin is represented in the Tocris library, but was toxic in our screening assay. The Spectrum Collection contains two forskolin-related compounds, colforsin and desacetylcolforsin. Colforsin, a water-soluble derivative of forskolin, was identified as a hit in the primary screen, and retested positive in all subsequent tests (see also below); it appeared to be less toxic than forskolin, whereas desacetylcolforsin was toxic at the concentration used. The identification of both IBMX and colforsin as hits in the primary screen confirmed that the assay conditions used were efficient at detecting expected hit compounds.

Secondly, we compared the scores for all compounds that were duplicated in both compound libraries. Chemoinformatics analysis of the Tocris and Spectrum libraries identified 155 compounds represented in both libraries, 65% of which (100/155) had exactly the same *vcanb* score average from the two individual screens. 39 (25%) of the 155 duplicate compounds yielded a *vcanb* score average that differed by 1--2 units between the two libraries; 12 (8%) of the compounds yielded a *vcanb* score average that differed by 3--6 units, whereas only 4 (3%) compounds had a score average that differed by 7--9 units. In summary, 90% (139/155) of the compounds common to both libraries showed similar scores for the *vcanb* assay from each library (scores differing by ≤2 units), whereas 10% (16/155) of the compounds resulted in differing levels of *vcanb* down-regulation between the two different libraries. After retesting, the difference between the two *vcanb* score averages for nine of these compounds was reduced; however, for seven compounds, the scores between the two libraries remained significantly different. These discrepancies could be either due to differences in compound purity between the two suppliers, or could be due to experimental error (e.g. in the concentration used, or during the ISH protocol). In cases where the same compound was scored as toxic in one assay and not in another, the health condition of the embryos in a particular well could be the underlying reason. Duplicated compounds have been included in the data for each library in the polar scatter plots ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

The top 91 hit compounds from both libraries (29 from Tocris, 62 from Spectrum) that scored A--C in all three *vcanb* assays were combined to give a complete list of 89 unique compounds, with baicalein and gedunin present in both libraries. The list covers a wide spectrum of naturally-derived and synthetic molecules, with known and unknown functions ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The hit compounds with known functions include calcium channel blockers, antifungal, anti-inflammatory, antihyperlipidemic, antibacterial and anthelmintic agents, as well as compounds with known antineoplastic and vasodilatory properties.

Secondary screen for rescue of *mbp* expression, and identification of false positives {#s2-7}
--------------------------------------------------------------------------------------

The two retests for *vcanb* expression significantly reduced the possibility of false-positive results due to experimental error (e.g. in the ISH protocol), but the list of hits could still contain false-positive compounds that may generally inhibit transcription. In order to eliminate such compounds, we exploited the expression of *mbp* as a secondary screening assay, scoring for rescue of expression around the posterior lateral line ganglion (PLLg) ([Figure 4A](#fig4){ref-type="fig"}; Materials and methods). This counter screen has the advantage of assessing for up-regulation (restoration) of *mbp* expression in mutant embryos, in contrast to the down-regulation of *vcanb* expression in the primary screen. All compounds that passed the first retest for *vcanb* (89 compounds in total) were subjected to this secondary assay for *mbp* expression. We used the same assay format and treatment time window as for *vcanb*, as we had previously found that treatment with IBMX between 60 and 90 hpf was also able to rescue *mbp* expression in *adgrg6* mutants (not shown).

Following two experimental repeats (*n* = 6 fish tested per drug), compounds were categorised into groups based on their average *mbp* score. These included groups of compounds that showed rescue of the mutant phenotype (an increase of *mbp* expression, specifically around the PLLg); no rescue (*mbp* expression equivalent to that in untreated *adgrg6^tb233c^* mutants), and those that resulted in a decrease in *mbp* expression, as shown in [Figure 4A](#fig4){ref-type="fig"}. We identified 41 compounds (12 from Tocris, 29 from Spectrum) that rescued *mbp* expression and thus represent possible modulators of Adgrg6 pathway ([Figure 4B,C](#fig4){ref-type="fig"}; [Table 1](#table1){ref-type="table"}). Twenty-eight hit compounds (15 from Tocris, 13 from Spectrum) strongly down-regulated *vcanb* expression but did not affect *mbp* expression in *adgrg6^tb233c^* mutants. These could represent compounds that can rescue *vcanb* expression in an inner ear-specific or Adgrg6-independent manner. Alternatively, as all the assays were carried out at a single concentration (25 μM), it is possible that some or all of these compounds could rescue *mbp* expression at a higher concentration (as is the case for IBMX with the *fr24* allele). The 28 members of this group are structurally and functionally diverse ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Finally, 22 compounds (two from Tocris, 20 from Spectrum) reduced the expression of both *vcanb* and *mbp.* This latter group---potential false positives in the *vcanb* assay---could represent general inhibitors of transcription or development, and were excluded from further analysis, resulting in a final list of 68 hit compounds ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The heat map in [Figure 5A](#fig5){ref-type="fig"} displays these groups using data from each of the screens and retests and clusters the compounds based on their activity.

![Heatmap of the assay results and network analysis for 68 compounds identified in the *vcanb* screen.\
(**A**) Heatmap of the assay results for each of the 68 hit compounds. Each box represents an embryo screened in each of the three assays (*vcanb, mbp* and *fr24*) as listed at the bottom of the heatmap. Each row corresponds to a different compound. Colours correspond to the scoring system used for each screen (0--3), with dark green, a strong hit (rescue of the mutant phenotype); yellow, no rescue; white, no data; white with red cross, toxic. Compounds were sorted based on the average score for *mbp* with strongest rescue at the top. The bracket indicates the 41 compounds that rescued both *vcanb* and *mbp* expression in *adgrg6^tb233c^* mutants and thus represent putative Adgrg6 pathway modulators. Abbreviations: C, colforsin; I, IBMX. (**B**) Network analysis based on structural similarity, showing all 3120 compounds from the two libraries. Compounds that rescued *mbp* expression are shown as larger nodes; compounds that did not rescue *mbp* expression are shown as smaller nodes. The colours used for compounds/nodes correspond to categories A--G (as indicated in [Figure 3](#fig3){ref-type="fig"}) and the two clusters of structurally similar compounds highlighted in [Figure 4](#fig4){ref-type="fig"} are also shown here. An interactive version of this figure can be accessed and mined at: <https://adlvdl.github.io/visualizations/network_whitfield_vcanb_mbp/index.html>.](elife-44889-fig5){#fig5}

10.7554/eLife.44889.016

###### List of the 41 hit compounds that rescued the expression of both *vcanb* and *mbp* in *adgrg6^tb233c^* mutants, thus representing putative Adgrg6 pathway modulators.

The table includes the plate and well ID, along with known activities and the average score from nine *adgrg6^tb233c^* embryos in the *vcanb* assay, from six *adgrg6^tb233c^* embryos in the *mbp* assay and from three *adgrg6^fr24^* embryos in the *fr24* assay. Grey shading indicates compounds presumed to interact with Adgrg6 receptor directly; yellow shading indicates compounds presumed to be downstream effectors of the pathway. Abbreviations: DE, dead embryos; ND, no data; S, Spectrum; T, Tocris. \*Note that cilnidipine can rescue *fr24* at 40 µM (data not shown). See also [Table 1---source data 1](#table1sdata1){ref-type="supplementary-material"}.

10.7554/eLife.44889.017Table 1---source data 1.Source data for [Table 1](#table1){ref-type="table"}.

  \#   Plate   Well   Compound name                               Known activity                                                                  *vcanb* score   *mbp* score   *fr24* score
  ---- ------- ------ ------------------------------------------- ------------------------------------------------------------------------------- --------------- ------------- --------------
  1    S18     C09    CARAPIN-8(9)-ENE                            undetermined                                                                    0.00            8.50          9.00
  2    S25     D08    3-ISOBUTYL-1-METHYLXANTHINE (IBMX)          phosphodiesterase inhibitor, non-selective adenosine receptor antagonist        2.00            8.50          9.00
  3    S17     F05    DEOXYGEDUNIN                                neuroprotective                                                                 2.00            8.00          9.00
  4    S23     F10    DIHYDROFISSINOLIDE                          undetermined                                                                    2.67            7.50          9.00
  5    S04     B02    IVERMECTIN                                  antiparasitic                                                                   2.33            7.00          9.00
  6    T01     F06    SC-10                                       protein kinase C activator, NMDA receptor activator                             5.67            6.50          9.00
  7    T01     H11    1,3-Dipropyl-8-phenylxanthine               Selective adenosine A1 receptor antagonist                                      3.33            6.50          9.00
  8    S17     E02    3-DEOXO-3beta-ACETOXYDEOXYDIHYDROGEDUNIN    undetermined                                                                    0.00            6.50          9.00
  9    T11     F07    Cilnidipine\*                               dihydropyridine N- and L-type Ca^2+^ channel blocker                            2.00            6.50          9.00
  10   S13     F03    AMIODARONE HYDROCHLORIDE                    coronary vasodilator, Ca^2+^ channel blocker                                    5.00            6.50          9.00
  11   S06     E02    HYDROCORTISONE HEMISUCCINATE                glucocorticoid                                                                  3.67            6.00          9.00
  12   T01     C04    (RS)-(Tetrazol-5-yl)glycine                 highly potent NMDA receptor agonist                                             3.00            5.00          9.00
  13   S02     E05    LOMEFLOXACIN HYDROCHLORIDE                  antibacterial                                                                   5.33            5.00          9.00
  14   S13     E04    ETHAMIVAN                                   CNS & respiratory stimulant                                                     4.67            5.00          9.00
  15   T08     B04    CGS 15943                                   potent adenosine receptor antagonist                                            5.33            4.50          9.00
  16   S13     E09    ASTEMIZOLE                                  H1 antihistamine (nonsedating)                                                  4.67            4.50          9.00
  17   T02     A09    SKF 91488 dihydrochloride                   histamine N-methyltransferase inhibitor                                         3.00            4.00          9.00
  18   S25     F05    11alpha-HYDROXYPROGESTERONE HEMISUCCINATE   glucocorticoid                                                                  2.67            4.00          9.00
  19   T14     A07    Efonidipine hydrochloride monoethanolate    dihydropyridine L-type and T-type Ca^2+^ channel blocker                        3.67            4.00          9.00
  20   T05     C09    Nifedipine                                  dihydropyridine L-type Ca^2+^ channel blocker                                   4.33            7.00          8.00
  21   T05     E08    CGP 37157                                   antagonist of mitochondrial Na^+^/Ca^2+^ exchange                               3.67            6.50          8.00
  22   S05     D03    DANAZOL                                     anterior pituitary suppressant, anti-estrogenic                                 1.00            5.00          8.00
  23   S18     H09    XANTHYLETIN                                 undetermined                                                                    1.00            4.50          8.00
  24   S18     A06    FERULIC ACID                                antineoplastic, choleretic, food preservative                                   3.67            4.00          8.00
  25   S18     F02    alpha-DIHYDROGEDUNOL                        undetermined                                                                    2.33            4.00          8.00
  26   T05     F04    (S)-(+)-Niguldipine hydrochloride           dihydropyridine L-type Ca^2+^ channel blocker, α1 antagonist                    3.67            5.00          7.00
  27   T07     F02    Tracazolate hydrochloride                   subtype-selective GABA~A~allosteric modulator                                   2.33            4.50          7.00
  28   S10     E02    NIMODIPINE                                  dihydropyridine L-type Ca^2+^ channel blocker                                   0.33            7.00          6.00
  29   S17     E06    3beta-ACETOXYDEOXODIHYDROGEDUNIN            undetermined                                                                    2.00            4.50          5.00
  30   S17     F02    DIHYDROGEDUNIN                              undetermined                                                                    1.67            5.00          2.00
  31   S22     F09    TANGERITIN                                  undetermined                                                                    1.33            5.50          1.00
  32   S10     F07    COLFORSIN                                   adenylate cyclase activator, antiglaucoma, hypotensive, vasodilator             0.00            9.00          0.00
  33   T04     G02    Imiloxan hydrochloride                      selective α~2B~-adrenoceptor antagonist                                         0.67            9.00          ND
  34   S24     C03    3alpha-ACETOXYDIHYDRODEOXYGEDUNIN           undetermined                                                                    0.33            8.50          DE
  35   S11     E02    EZETIMIBE                                   antihyperlipidemic (sterol absorption inhibitor)                                2.00            7.50          0.00
  36   S10     E06    NITRENDIPINE                                dihydropyridine L-type Ca^2+^ channel blocker                                   1.33            7.00          ND
  37   S11     E08    ROSUVASTATIN CALCIUM                        antihyperlipidemic                                                              0.00            6.00          0.00
  38   S22     C07    DEMETHYLNOBILETIN                           undetermined                                                                    0.00            6.00          0.00
  39   S22     G11    HEXAMETHYLQUERCETAGETIN                     undetermined                                                                    0.00            5.50          DE
  40   S22     F08    NOBILETIN                                   matrix metaloproteinase inhibitor, antineoplastic, anti-ERK, NF-κB suppressor   0.00            5.00          DE
  41   S12     H07    PREGNENOLONE SUCCINATE                      glucocortcoid, antiinflammatory                                                 4.67            4.00          DE

Compounds that can rescue both inner ear and myelination defects {#s2-8}
----------------------------------------------------------------

The 41 compounds that could both down-regulate *vcanb* expression and restore *mbp* expression to wild-type levels in *adgrg6^tb233c^* mutants, presumed modulators of the Adgrg6 signalling pathway ([Table 1](#table1){ref-type="table"}), are highlighted on the final combined polar scatter plot ([Figure 4F](#fig4){ref-type="fig"}). Although hit compounds are scattered around the plot, some clustering is evident, and we chose two groups for further analysis ([Figure 4F](#fig4){ref-type="fig"}; boxes at 300, 2500); these clusters are also clearly seen in a compound network display based on structural similarity in [Figure 5B](#fig5){ref-type="fig"}; interactive version at <https://adlvdl.github.io/visualizations/network_whitfield_vcanb_mbp/index.html>). Groups with five or more compounds included the pyridines (cluster 1, [Figures 4D](#fig4){ref-type="fig"} and [5B](#fig5){ref-type="fig"}) and the tetranortriterpenoids (gedunin derivatives) (cluster 2, [Figures 4D](#fig4){ref-type="fig"} and [5B](#fig5){ref-type="fig"}). The pyridine cluster included one pyrazolopyridine and six dihydropyridines, a class of L-type calcium channel blockers with vasodilatory properties (reviewed in [@bib83]). The gedunins are a family of naturally occurring compounds, previously attributed with antineoplastic and neuroprotective effects ([@bib35]; [@bib79]).

A selection of compounds was chosen for further study ([Figures 6](#fig6){ref-type="fig"}--[8](#fig8){ref-type="fig"}). Two dihydropyridines, nifedipine and cilnidipine, were chosen from cluster 1. The third compound chosen was tracazolate hydrochloride, a pyrazolopyridine derivative belonging to the nonbenzodiazepines and a known γ-aminobutyric acid A (GABA~A~) modulator ([@bib82]), which strongly down-regulated *vcanb* expression to wild-type levels. FPL 64176 was also chosen for further analysis, based on its potent efficacy in down-regulating *vcanb,* and the fact that it was the only calcium channel modulator ([@bib45]) that did not rescue *mbp* expression efficiently. Initial experiments to repeat the rescue of the *vcanb* and *mbp* expression with freshly-sourced compounds from alternative suppliers (see Materials and methods) confirmed that the pyridines cilnidipine, nifedipine and tracazolate hydrochloride were able to decrease otic *vcanb* expression and increase *mbp* expression around the PLLg in mutant embryos for the *tb233c* allele, whereas FPL 64176 was able to reduce *vcanb* expression but was unable to restore *mbp* expression to wild-type levels ([Figure 6C](#fig6){ref-type="fig"}).

![Hit compounds from the *vcanb* screen vary in their ability to restore *mbp* expression in *adgrg6^tb233c^* mutant embryos.\
(**A**) Section of the heatmap in [Figure 5A](#fig5){ref-type="fig"} showing the results for nifedipine, cilnidipine, tracazolate hydrochloride and FPL 64176. (**B**) Enlargement of the dihydropyridine cluster (cluster 1 in [Figures 4G](#fig4){ref-type="fig"} and [5B](#fig5){ref-type="fig"}), highlighting cilnidipine and nifedipine. Compounds that rescued *mbp* expression are shown as larger nodes, whereas compounds that did not rescue *mbp* expression are shown as smaller nodes. The relationship of nilvadipine (green circle) to the other compounds in this cluster is also illustrated. (**C**) (i--vii) Lateral images of the inner ear at 4 dpf stained for *vcanb* by ISH. (i) Wild-type, (ii) *adgrg6^tb233c^* mutant treated with DMSO as a control, (iii--vii) treatment of *adgrg6^tb233c^* mutants with test compounds at 25 µM, with the exception of nilvadipine, which was tested at 22.5 µM. (viii--xiv) *mbp* mRNA expression of embryos treated as indicated above. Black arrowheads indicate *mbp* expression around the PLLg; white arrowhead in (ix) indicates the position of the PLLg in the untreated mutant, lacking *mbp* expression. Nifedipine, cilnidipine, tracazolate hydrochloride and nilvadipine all rescued *mbp* expression around the PLLg, whereas FPL 64176 did not rescue *mbp* expression around the PLLg so efficiently. (xv--xix) Representation of the chemical structures of the five compounds tested. Scale bar in (i), 50 µm (applies to i-vii); scale bar in viii, 50 µm (applies to viii--xiv).](elife-44889-fig6){#fig6}

![Selected hit compounds rescue the *adgrg6^tb233c^* mutant ear phenotype in a dose-dependent manner.\
*adgrg6*^*tb233c*^ homozygous embryos were exposed to a 1.5-fold dilution series of concentrations (ranging from 0.3 μM to 33.7 μM), tailored to the toxicity of nifedipine, cilnidipine, tracazolate hydrochloride and FPL 64176. IBMX (50 μM and/or 100 μM) was used as a positive control; DMSO (1%) was used as a negative control. Embryos were treated between 60--110 hpf prior to fixation and analysis for *vcanb* expression by whole-mount in situ hybridisation. Embryos were scored in accordance with two scoring systems, in order to assess the localisation (**A**) and the intensity (**B**) of *vcanb* ISH staining. (**A**) (i--iv) Scoring system used to assess the number of projections (p) with *vcanb* ISH staining. (v--viii) Charts showing the number of embryos that scored 0 p, 1 p, 2 p, or 3 p. (**B**) (i--iv) Charts showing the number of embryos that scored 0, 1, 2, or 3, according to the scoring system shown in [Figure 3A](#fig3){ref-type="fig"}. (**C**) (i--vi) Live DIC images of 110 hpf (or 90 hpf for FPL 64176-treated embryos) *adgrg6^tb233c^* mutants treated with the compounds shown above. Dorsal views with anterior to the left. (i'--vi') Lateral views of the inner ear of the embryos depicted in i--vi, showing rescue of pillar fusion (arrowheads) following treatment. (**D**) Measurements of the ear-to-ear width were taken from live embryos mounted dorsally and photographed at a focal plane that highlighted the largest visible dimensions (see [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Error bars represent the mean ± standard deviation. Combined data from two experimental repeats. Scale bars: 50 μm.\
10.7554/eLife.44889.023Figure 7---source data 1.Source data for the dose-response experiments shown in [Figure 7D](#fig7){ref-type="fig"}.](elife-44889-fig7){#fig7}

![Assay for rescue of the *fr24* strong allele distinguishes compounds likely to rescue downstream, or at the level of, the Adgrg6 receptor.\
(**A**) Section of the heatmap in [Figure 5A](#fig5){ref-type="fig"} showing the results for colforsin, dihydrofissinolide, deoxygedunin and carapin-8(9)-ene. (**B**) Enlargement of the cluster containing gedunin-related compounds (cluster two in [Figures 4G](#fig4){ref-type="fig"} and [5B](#fig5){ref-type="fig"}), highlighting deoxygedunin, dihydrofissinolide and carapin-8(9)-ene. Compounds that rescued *mbp* expression are shown as larger nodes; compounds that did not rescue *mbp* expression are shown as smaller nodes. (**C**) (i--x) The inner ear at 4 dpf stained for *vcanb*. Lateral views; anterior to the left. Scale bar (applies to panels i--x): 50 µm. (i) *adgrg6^tb233c^*/DMSO mutant control. (ii -- v) Treatment of *adgrg6^tb233c^* mutants with the compounds at 25 µM indicated was able to rescue the *tb233c* mutant ear phenotype to variable degrees. (vi) *adgrg6^fr24^*/DMSO mutant control. (vii--x) Treatment of *adgrg6^fr24^* mutants with colforsin rescued otic *vcanb* expression in the *fr24* allele, whereas treatment with dihydrofissinolide, deoxygedunin and carapin-8(9)-ene was unable to rescue the *fr24* ear phenotype. (xi--xiv) Representation of the chemical structure of the four compounds tested. Note the structural similarity between deoxygedunin, dihydrofissinolide and carapin-8(9)-ene.](elife-44889-fig8){#fig8}

To examine whether the network clustering was able to predict functional activity, we selected an additional four dihydropyridines that were not represented in the Tocris or Spectrum libraries, and tested whether they could also rescue *vcanb* expression in *adgrg6^tb233c^* mutants. Nilvadipine, nemadipine-A, felodipine and lercanidipine are all dihydropyridine calcium channel blockers of the type used to treat hypertension. Nilvadipine is structurally closely related to nifedipine ([Figure 6B](#fig6){ref-type="fig"}); as predicted, it gave a dose-responsive rescue of otic *vcanb*, with full rescue at 50.6 µM ([Figure 6Cvii](#fig6){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), and a strong rescue of *mbp* expression at 22.5 µM ([Figure 6Cxiv](#fig6){ref-type="fig"}). The three other compounds showed a range of efficacy in the *vcanb* assay at 25 μM, with nemadipine-A showing complete rescue, felodipine mild rescue and lercanidipine no rescue ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). However, a higher concentration of lercanidipine (50 μM) was able to rescue *vcanb* expression, whereas felodipine continued to show mild rescue at 40 µM ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

We also tested a higher concentration of a Tocris compound from the pyridine cluster, (±)-Bay K 8644, which had originally scored as a non-hit in the primary screen (25 µM). We found that this compound rescued otic *vcanb* expression effectively at 40 μM, and in fact also gave a mild rescue at 25 µM in this experiment ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Interestingly, (±)-Bay K 8644 is a dihydropyridine that acts as a calcium channel agonist with similar activity to FPL 64176 ([@bib30]; [@bib64]). All compounds tested from cluster one share a large common substructure composed of a pyridine ring and its five substitutions (one phenyl ring, two ester groups, and two methyl groups). Felodipine and nemadipine-A both have several halogen atoms bound to the phenyl ring, whereas on most of the other compounds a nitro group is bound to the phenyl ring. The main difference between the dihydropyridine structures comes from the variety of different esters attached to the pyridine ring ([Figure 6C](#fig6){ref-type="fig"}; [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}).

Nifedipine, cilnidipine, tracazolate hydrochloride and FPL 64176 rescue otic defects in *adgrg6^tb233c^* mutants in a dose-dependent manner {#s2-9}
-------------------------------------------------------------------------------------------------------------------------------------------

The four compounds shown in [Figure 6](#fig6){ref-type="fig"} were also selected for dose-response assessment, by exposing *adgrg6^tb233c^* embryos to concentrations ranging from 0.3 μM to 222.2 μM between 60--110 hpf. Nine embryos were tested for each concentration, and a 1.5-fold dilution series of each drug was used. ISH analysis of the 110-hpf embryos revealed a robust, dose-dependent down-regulation of *vcanb* mRNA expression in response to treatment with all four drugs ([Figure 7](#fig7){ref-type="fig"}). Expression of *vcanb* mRNA was assessed by annotating each embryo with two scores, one representing the number of unfused projections stained ([Figure 7A](#fig7){ref-type="fig"}), and the other representing the intensity of the stain ([Figure 7B](#fig7){ref-type="fig"}, score as in [Figure 3A](#fig3){ref-type="fig"}). All four drugs were able to reduce both the intensity of the ISH staining and the number of projections stained in the ear in a dose-dependent manner. For each of the four drugs, the intensity of the *vcanb* staining decreased even after treatment with low doses, whereas higher doses were needed to reduce the number of the projections stained.

In order to investigate whether other aspects of the ear phenotype in *adgrg6^tb233c^* mutants could be rescued by compound treatment, the inner ears of live treated embryos were observed with differential interference contrast (DIC) optics at 110 hpf (or 90 hpf in the case of FPL 64176, due to its toxicity). Consistent with the *vcanb* scores for the number of projections stained, live DIC images of the inner ear revealed a dose-dependent rescue of projection fusion and pillar formation, which was greater at higher doses ([Figure 7C](#fig7){ref-type="fig"}). As *adgrg6^tb233c^* mutants have a swollen ear phenotype ([@bib21]), measurements of the ear-to-ear width, normalised for size differences between individuals, were taken from photographs of live embryos mounted dorsally. The results showed a dose-dependent reduction in ear swelling with increased concentration of the four drugs ([Figure 7D](#fig7){ref-type="fig"}; [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). LD50 concentrations were also determined for each of the four compounds and ranged from 19.2 μM (cilnidipine) to 51.7 μM (tracazolate hydrochloride) ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}).

Test for rescue of *vcanb* expression in the *fr24* allele: screen for Adgrg6-specific ligands {#s2-10}
----------------------------------------------------------------------------------------------

The initial screen was performed on the hypomorphic *tb233c* allele. We differentiated our hit compounds further by re-screening for *vcanb* expression in a strong *adgrg6* allele, *fr24* ([Figure 1B](#fig1){ref-type="fig"}), to identify compounds that could potentially interact directly with the Adgrg6 receptor itself. We predicted that any compounds able to rescue both alleles (such as IBMX at higher concentrations) are likely to act downstream of the receptor. On the other hand, hits that rescued *tb233c*, but were not able to rescue *fr24,* could potentially act as putative agonistic ligands for the Adgrg6 receptor. Of the 41 hit compounds able to rescue both *vcanb* and *mbp* in the *tb233c* allele, we identified 10 compounds that also rescued *vcanb* expression in the *fr24* screen (score sum 0--7 in [Table 1](#table1){ref-type="table"}, yellow), 12 compounds that gave a partial or inconclusive rescue (white), and 19 compounds that did not affect *vcanb* expression in the *fr24* screen (score sum nine in [Table 1](#table1){ref-type="table"}, grey). The first group (yellow) are presumed to act downstream of the Adgrg6 receptor, and include colforsin, which tested positive in all assays and is a known activator of adenylyl cyclase, supporting this interpretation ([Figure 8](#fig8){ref-type="fig"}). The last class (grey) are of particular interest as they represent candidates for molecules that may interact directly with the receptor. Examples of the difference in ability to rescue the two *adgrg6* alleles between the two classes can be seen in [Figure 8C](#fig8){ref-type="fig"}.

Interestingly, four of the 19 compounds in the last group are in the cluster of gedunin derivatives identified in [Figure 4](#fig4){ref-type="fig"} (cluster 2), with deoxygedunin being one of the top ten most potent drugs able to rescue the *tb233c* allele. The compound network shows that 38 compounds with structural similarity to the gedunins are represented in the two libraries ([Figures 5](#fig5){ref-type="fig"} and [8](#fig8){ref-type="fig"}). In the primary screens, 25/38 (66%) gedunin-related compounds affected *vcanb* expression to some extent (18 compounds in categories A--C and seven in D), nine compounds were inactive and four were toxic. The majority of the gedunin-related compounds that passed both rounds of retesting were later found also to rescue *mbp* expression (8/10, 80%). The shared structural characteristics of the gedunin group may give useful clues for candidate structures of agonistic ligands for Adgrg6. In summary, our study demonstrates a novel screening approach which, when combined with chemoinformatics analysis, is able to delineate both expected downstream rescuers of the Adgrg6 pathway and several candidates for drugs that may interact directly with the Adgrg6 receptor.

Discussion {#s3}
==========

Adhesion GPCRs are critical regulators of development and disease, driving cell-cell and cell-ECM communications to elicit internal responses to extrinsic cues. This study set out to identify positive modulators of the Adgrg6 signalling pathway, a key regulator of myelination and inner ear development in the zebrafish embryo. Use of a whole-animal phenotypic (mutant rescue) screen gave the potential to identify compounds affecting the entire Adgrg6 pathway in the correct cellular context. We have used a simple in situ hybridisation approach to assay *vcanb* expression in the inner ear of *adgrg6* mutants, exploiting an easily identifiable phenotype that could be scored manually. Following our primary screen of 3120 small molecules, we tested 89 hit compounds in a counter screen for rescue of the myelination defect in *adgrg6* mutant embryos. We identified 41 compounds that can both rescue *vcanb* expression in the inner ear and *mbp* expression in Schwann cells of *adgrg6* hypomorphic mutants, suggesting these are Adgrg6 pathway-specific modulators. Further analysis of a strong *adgrg6* allele, *fr24*, identified a subset of 19 compounds that are potential direct interactors of the Adgrg6 receptor. This analysis, combined with chemoinformatics analysis of the identified hit compounds, has identified clusters of compounds acting at different levels of the Adgrg6 pathway.

An optimal drug screening assay design identifies the maximum number of hit compounds with the minimum number of false positives and false negatives. Chemical screening assays using zebrafish range from simple morphology screens ([@bib95]) through to high-tech, automated methods for quantitative image analysis ([@bib19]) or behavioural analysis ([@bib13]; [@bib66]) (reviewed in [@bib36]). We used an in situ hybridisation screen to analyse gene expression changes, as this has the advantages of being scalable to different sized projects and relatively inexpensive to perform---with results that are stable and reproducible. Spatial resolution of staining patterns can be accurately scored: expression pattern screens have recently been used to identify small molecules that can induce subtle differences in gene expression domains along the pronephros ([@bib62]) and in the somites ([@bib68]). Although quantification of gene expression levels is less reliable with an enzymatic reaction compared with a fluorescent signal, we utilised the strong contrast between the high *vcanb* expression in the ear of *adgrg6* mutant fish compared with the low expression in a small dorsal region of the wild-type ear at four dpf to produce a robust scoring system for our phenotype rescue.

Relatively few zebrafish screens have been undertaken to identify compounds that can increase myelination ([@bib15]; [@bib19]) or restore myelination in neuropathy models ([@bib96]), which is in part due to the complex distribution of glial cells in both the CNS and PNS. Performing the primary screen using an ear marker, *vcanb*, enabled us to bypass the difficulties of scoring and quantification of *mbp* staining on a large scale; instead, *mbp* expression was used as a counter screen on a limited number of cherry-picked hits. Contrary to the primary assays, which screened for down-regulation of *vcanb* expression, the counter screen assayed for up-regulation of *mbp* expression, enabling the identification of 21 false-positive compounds that down-regulate the expression of both genes (presumably by inhibiting transcription).

Determining the false-negative rate for any screen is difficult. In our assay we used only one concentration of compound (25 µM), so it is likely that some of the compounds that were toxic or showed no effect at 25 µM---and thus eliminated from our screen---would be effective at lower or higher concentrations, respectively. One possibility would be to run a parallel screen at a lower or higher concentration or use an alternative protocol with shorter incubation times, an approach that has recently proved successful at identifying different compounds influencing segmentation in zebrafish ([@bib68]). Here, the compounds were found to be most active in the range of 10--50 µM, supporting our choice of 25 µM for the primary screen. However, increasing the number of replicates with different drug concentrations or assay conditions has significant implications on the cost and time taken to complete the screen, reducing the number of compounds analysed and the potential hits identified. An alternative method is to use a structural network to select and prioritise candidate compounds that have a similar structure to hit compounds and test these at different concentrations. Using this approach, we identified (±)-Bay K 8644 as an additional hit from the pyridine cluster when tested at a higher concentration. Our minimum estimate for the false-negative rate is 5%, based on the seven compounds (out of a total of 155) that were duplicated in both libraries and had a significantly different score after retesting, being classified as a hit in one library but not in the other. It is possible that this is due to differences in chemical purity from the different suppliers. Other false-negative compounds could include those that are unable to penetrate into the ear. Neomycin, for example, is toxic to the superficial hair cells of the lateral line system, but is ineffective on inner ear hair cells unless microinjected into the ear ([@bib14]). Other compounds that we will have missed could include myelination-specific compounds, as the primary assay scored for the ear phenotype only. Given that several compounds were positive hits for the rescue of *vcanb* in the ear and negative for *mbp*, it is likely that tissue-specific functions of Adgrg6 are mediated through different downstream pathways or are stimulated by different ligands.

Our positive control compound, IBMX, was identified independently through our screen as a category A hit. The hit compound colforsin was found to be more potent and less toxic than the related control compound forskolin, and had the highest score in every assay, showing full rescue of the strong *fr24* allele. Both these observations highlight the robustness of the assay and the consistency of the scoring process. In total, the final number of hit compounds identified was similar in both the compound libraries screened, with 42 compounds identified from the Spectrum library (2.1%) and 27 compounds from the Tocris library (2.4%). These hit rates are comparable to those found in other similar screens ([@bib5]; [@bib85]; [@bib92]).

Chemoinformatics analysis and visualisation of the results provided additional context to the identified hit compounds. The polar scatter plot displayed an initial overview of the results and allowed the identification of six different structurally-related clusters of active compounds with similar structure. The compound network focused the analysis on highly detailed similarity relationships inside each compound cluster, yielding a wealth of structure-activity relationship information that could prove very useful for any future optimisation of the identified hit compounds. Seven of the 41 hit compounds that rescued *vcanb* and *mbp* expression are Ca^2+^-channel modulators. Six of these (nifedipine, cilnidipine, nitrendipine, nimodipine, efonidipine, niguldipine) belong to the chemical group of dihydropyridines (cluster 1), and initial investigations into compounds with similar structures identified four additional compounds in this class. Several dihydropyridines are known to have neuroprotective effects in mammalian models. Nimodipine, for example, has been shown to trigger remyelination in a mouse model of multiple sclerosis and to improve repair in peripheral nerve crush injuries in rats ([@bib72]; [@bib80]), and some compounds have shown promise at clearing toxic proteins in animal models of neurodegeneration, including felodipine ([@bib75]) and nilvadipine ([@bib56]). As dihydropyridines have been reported to inhibit cAMP phosphodiesterases ([@bib74]), protection of cAMP from degradation might be another mechanism whereby these molecules exert their ameliorating action on the *adgrg6* mutant phenotype.

Phenotypic screens are advantageous for assessing models of multifactorial pathological conditions, such as hereditary neuropathies and cancer (reviewed in [@bib6]). However, one of the challenges for phenotypic screening is the identification of the specific target for any hit compound, as multiple pathways and different cell types can contribute to a positive read-out in the screening assay. Our aim was to identify compounds that could potentially interact directly with the Adgrg6 receptor. We were able to separate hit compounds into different groups based on their ability to rescue otic phenotypes caused by missense (*tb233c*) and nonsense (*fr24*) mutations. In total, we found 19 hits that could rescue *vcanb* expression and *mbp* expression in the *tb233c* allele, but were unable to rescue the *fr24* allele. We hypothesise that the *fr24* allele is unable to produce the full-length Adgrg6 protein including the CTF, and therefore any compounds that interact directly with the receptor would not be able to rescue any CTF-dependent function in this strong allele. Further analysis will be needed to determine whether any of these compounds can bind directly to the Adgrg6 receptor, for example by assessing stimulation of cAMP and direct binding in in vitro assays. However, this approach of using a combination of null and hypomorphic alleles in zebrafish whole-organism screening with the aim of identifying target-specific compounds is particularly exciting and one that the advent of CRISPR/Cas9 technology is placed to take full advantage of, since it is now possible to generate designer mutations in the zebrafish through homology-directed repair ([@bib29]; [@bib33]; [@bib41]).

It is of interest to note that one of the main groups of compounds identified as potential interactors of the receptor in the *fr24* screen is a cluster of gedunin derivatives (cluster 2). One of these compounds, deoxygedunin, has previously been identified as a TrkB agonist that has neuroprotective properties ([@bib53]), can promote axon regeneration after nerve injury ([@bib20]), and, interestingly, has been found to protect the vestibular ganglion from degeneration in mice mutant for *BDNF* ([@bib35]). More recently, gedunin derivatives, including 3-α-DOG, have been shown to act as partial agonists for the closely related aGPCR, ADGRG1 (formerly GPR56) ([@bib78]), a key regulator of myelination in both the CNS and PNS ([@bib1]; [@bib2]; [@bib22]; [@bib70]). While further work will be necessary to determine if gedunin-type molecules can also bind and activate zebrafish Adgrg6 by interacting directly, these studies set a precedent for this type of interaction.

GPCRs can be modulated by the membrane lipid cholesterol, where interactions with the 7TM domain can provide plasticity for the receptors by altering their stability and structure ([@bib31]; [@bib63]). In addition, cholesterol can activate the hedgehog signalling pathway directly by binding to the extracellular domain of the GPCR Smoothened ([@bib31]; [@bib46]). Although cholesterol was not identified as a hit in our primary screen, we did identify two cholesterol-lowering drugs, ezetimibe ([@bib3]) and rosuvastatin ([@bib34]), as putative modulators of the Adgrg6 pathway. Whether these act by altering the activity of Adgrg6 through altering cholesterol levels remains to be determined.

In addition to the dihydropyridines (cluster 1) and the tetranortriterpenoid (gedunin-derived) compounds (cluster 2), there are also clusters of steroid hormones (danazol, hydroxyprogesterone, pregnenalone succinate, hydrocortisone hemisuccinate) and flavonoid compounds (baicalein, tangeritin, nobiletin, dimethylnobiletin, hexamethylquercetagetin). The flavonoids are a group of molecules with wide ranging activities, including anti-cancer ([@bib47]) and neuroprotective properties (reviewed in [@bib11]). All four *O*-methylated flavonoids that rescued *vcanb* and *mbp* expression in *tb233c* mutants were also able to rescue *fr24* allele in our assay, suggesting that they act downstream of the Adgrg6 receptor.

Our screen identified 28 compounds that down-regulated *vcanb* expression, but did not rescue *mbp* expression, which may provide useful tools to manipulate semicircular canal formation in vivo. Versican and other chondroitin sulphate proteoglycans (CSPGs) are associated with a number of human pathologies; Versican overexpression has been shown to be strongly involved in inflammation, cancer progression and the development of lung disorders (reviewed in [@bib4]; [@bib67]; [@bib91]). CSPGs and hyaluronan are components of the inhibitory scar that forms at the site of injury after CNS damage, preventing axon regeneration ([@bib76]). In addition, CSPGs have been shown to inhibit the ability of oligodendrocytes to remyelinate axons, a process that is reversed by reduction of CSPG levels ([@bib40]; [@bib60]). Whether the down-regulation of CSPGs to promote remyelination occurs via a similar mechanism to that involved in Adgrg6-regulated projection fusion remains to be determined. However, it is of interest that a key regulator of myelination, Adgrg1, has also been recently shown to reduce fibronectin deposition and inhibit cell-ECM signalling to prevent metastatic melanoma growth ([@bib48]).

In conclusion, our data show that *vcanb* expression in the *adgrg6^tb233c^* mutant ear provides a robust, easy-to-use screening tool to identify drugs that target the Adgrg6 pathway. In combination with the different alleles available for *adgrg6* in zebrafish, this in vivo platform provides an excellent opportunity to find hit compounds that may be specific for Adgrg6 in counter screens. These may provide a starting point for the development of therapeutic approaches towards human diseases where *ADGRG6* or myelination is affected. We have identified groups of structurally-related compounds that can rescue *adgrg6* mutant defects, including those that are likely to act downstream of the Adgrg6 pathway, and others that are candidates for interacting with the Adgrg6 receptor. The chemical analysis and structural comparison of the compounds shown to be putative Adgrg6 receptor agonists will contribute to the elucidation of the physical properties responsible for ligand binding and will provide further insight on the underlying mechanism of Adgrg6 signalling.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

Standard zebrafish husbandry methods were employed ([@bib89]). To facilitate visualisation of in situ hybridisation (ISH) staining patterns, embryos of the *nacre* (*mitfa^w2/w2^*) strain (ZDB-GENO-990423--18), which lack melanophores ([@bib44]), but are phenotypically wild-type for expression of *vcanb* and *mbp*, were used as controls for all drug screening experiments. The wild-type strain used for dose-response experiments was London Wild Type (LWT). *adgrg6* mutant alleles used were *lau^tb233c^* (formerly *bge^tb233c^*) and *lau^fr24^* (ZDB-GENE-070117--2161) ([@bib21]; [@bib90]), and were raised on a pigmented background. In all cases shown, mutant embryos are homozygous for the respective allele. The transgenic strain used for imaging in [Figure 1](#fig1){ref-type="fig"} and in the videos expresses GFP throughout the otic epithelium, and was a gift of Robert Knight ([@bib7]). Prior to treatment, embryos were raised in E3 embryo medium ([@bib89]) at 28.5°C. We have used the term embryo throughout to refer to zebrafish embryos and larvae from 0 to 5 days post fertilisation (dpf).

Compound storage, aliquoting and administration to embryos {#s4-2}
----------------------------------------------------------

Chemical compounds from the Tocriscreen Total library (Tocris, Batch \#2884, 1120 compounds) and The Spectrum Collection (Microsource Discovery Systems, Batch \#100122, 2000 compounds) were arrayed in MultiScreen-Mesh 96-well culture receiver trays (Millipore) in columns 2--11 and diluted to 25 μM in E3 medium for drug screening. Control wells contained either IBMX (3-isobutyl-1-methylxanthine, Sigma, 50 μM and 100 μM), DMSO (Sigma, 1% in E3) or E3, in columns 1 and 12 (see diagram of the plate layout in [Figure 2](#fig2){ref-type="fig"}). Wild-type (LWT and *nacre*) and homozygous *adgrg6^tb233c^* mutant embryos were raised to 50 hpf at 28.5°C in E3 medium, dechorionated manually with forceps, and then incubated at 20°C overnight to slow down development and facilitate timing of experimental treatments. This regime reduced ear swelling, but did not reduce otic *vcanb* levels, in mutant embryos. Embryos at the 60 hpf stage were aliquoted at three embryos per well into MultiScreen-Mesh mesh-bottomed plates (Millipore) and transferred to the drug plate (receiver tray; see above). Assay plates were incubated at 28.5°C for 28 hr and the embryos were then transferred to 4% paraformaldehyde and stored at 4°C overnight. Embryos were bleached according to the standard protocol ([@bib81]) and stored at −20°C in 100% methanol until required for ISH. Hits identified in the primary screen were rescreened using the same protocol. Selected compounds were purchased separately from Sigma (nifedipine, cilnidipine, nilvadipine), Sigma LOPAC Collection (nemadipine-A, felodipine, lercanidipine), Cayman Chemicals (FPL 64176) and Santa Cruz Biotechnology (tracazolate hydrochloride).

Whole-mount in situ hybridisation analysis of gene expression {#s4-3}
-------------------------------------------------------------

Digoxigenin-labelled RNA probes for *vcanb* ([@bib37]) and *mbp* (*mbpa*) ([@bib12]) were prepared as recommended (Roche). Whole-mount ISH was performed using standard procedures ([@bib81]), modified for the Biolane HTI 16V in situ robot (Intavis) and MultiScreen-Mesh mesh-bottomed plates to increase throughput ([@bib5]). Stained embryos were scored manually by at least two people and any discrepancies between the results were re-analysed. For the dose-response data the results were blinded and re-scored to check for consistency.

Scoring systems for *vcanb* and *mbp* expression {#s4-4}
------------------------------------------------

To score the efficacy of the drugs in down-regulating *vcanb* mRNA levels, a scoring system from 0 to 3 was used, with 0 being the score for a very efficient drug (a 'hit') that can suppress *vcanb* expression back to almost wild-type levels, and 3 the score for a drug that did not have any effect on *vcanb* mRNA levels expressed in the *adgrg6* mutant ear. Scores 1 and 2 were given to drugs that showed an ability to down-regulate *vcanb* expression to some extent, with 1 given for a stronger down-regulation than 2 ([Figure 3A](#fig3){ref-type="fig"}). Drugs were then classified into categories A--E, according to the combined score from the three embryos treated with each drug ([Figure 3B](#fig3){ref-type="fig"}).

For the *mbp* counter screen ([Figure 4A,B](#fig4){ref-type="fig"}), a score of 3 was used for embryos where *mbp* mRNA expression was rescued to wild-type levels, a score of 2 for embryos that showed some *mbp* expression around the PLLg (weaker than wild-type levels) and a score of 1 in cases where the *mbp* expression was identical to the one seen in untreated *adgrg6^tb233c^* mutants (i.e. lacking *mbp* expression around the PLLg). The fact that *mbp* expression is not missing altogether from other areas of the PNS in *adgrg6^tb233c^* mutants allowed us to use a score of 0 in cases where *mbp* expression levels were lower than those typically seen in *adgrg6^tb233c^* mutants.

Hit selection {#s4-5}
-------------

Drugs categorised as A or B were considered successful and were cherry-picked into new drug assay plates for further testing. Drugs categorised as C were potentially interesting and a few were used to complete a 96-well cherry-pick plate (37/96 compounds). Drugs categorised as D and E were considered to show incomplete or no inhibition of *vcanb* expression, respectively. Drugs from category F caused severe developmental abnormalities, heart oedema, brain oedema or death at the end of the treatment and therefore were characterised as toxic. Category G represented drugs that were potentially corrosive, as no fish were found in these wells at the end of the treatment, although this could also have resulted from death of the embryos followed by digestion by microorganisms, or through experimental error. Drugs that fell into any of the categories D--G and most from category C (59) were eliminated from the assay and were not followed further. In addition, 10 compounds from category A and B were unable to be tested further due to compound availability issues.

Compounds taken forward for secondary assays were chosen by two criteria: 1. A final average score for three replicates (total nine embryos) with a category A--C; 2. No individual score \>7. In total, 91 compounds were picked for the counter screen, including two that were present in both libraries, resulting in 89 individual compounds. The screening pipeline is shown in [Figure 4G](#fig4){ref-type="fig"} and the subsequent grouping of compounds is described in [Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [8](#fig8){ref-type="fig"}.

Dose-response and LD50 assays {#s4-6}
-----------------------------

Selected compounds were tested in dose-response assays. In order to assess the ear swelling in drug-treated *adgrg6^tb233c^* mutant embryos, the ear-to-ear width was measured from photographs of live embryos mounted dorsally, and normalised for the size of the head, using CELLB software (for details, see [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

An LD50 curve was plotted for the adjusted exposure time (60--110 hpf), using 16 LWT wild-type embryos (biological replicates) per concentration. To avoid cross-contamination from dead embryos, each wild-type (LWT) embryo was kept in a separate well of a 96-well plate. At the end of each treatment, the number of dead embryos (no heartbeat for 10 s) was recorded.

Microscopy and photography {#s4-7}
--------------------------

Still images of live embryos were taken using an Olympus BX51 microscope, C3030ZOOM camera and CELLB software, and assembled with Adobe Photoshop. All micrographs are lateral views with anterior towards the left and dorsal towards the top, unless otherwise stated. For archiving, fixed and stained embryos were imaged in MultiScreen-Mesh plates containing 50% glycerol, using a Nikon AZ100 microscope with an automated stage (Prior Scientific). A compressed in-focus image was generated using the NIS-Elements Extended Depth of Focus software (Nikon).

Time-lapse imaging of live embryos was performed on a Zeiss Z.1 light-sheet microscope. *adgrg6^fr24^* homozygous mutant embryos in a transgenic background (see Animals) were mounted at 60 hpf in 0.7% agarose with anaesthetic (MS-222; 160 µg/ml) and 0.003% PTU (to prevent pigment formation). Images were taken of a dorsal view of the ear every 5 min (200 *z*-slices, 1 µm sections). A control time-lapse of a wild-type sibling embryo (images taken at 10 min intervals) was taken on a separate day. Images were cropped and a subset of *z-*slices through the anterior (*adgrg6^fr24^*) and posterior (phenotypically wild-type sibling) projections were used to make Maximum Intensity Projection videos of projection fusion in the wild-type sibling and the swollen projections in *adgrg6^fr24^* mutant embryo. The two videos do not correspond exactly to the same developmental stage.

Chemoinformatics analysis and data visualisation {#s4-8}
------------------------------------------------

Chemical structures of the library compounds represented as SMILES ([@bib87]) were obtained from vendor catalogues. Molecules were standardised using the wash procedure of MOE (Chemical Computing Group Inc, Molecular Operating Environment (MOE), Montréal, QC, 2011), accessed through KNIME ([@bib9]). Standardised molecules were analysed using RDKit (RDKit: Open-Source Cheminformatics, <http://www.rdkit.org/>, accessed 06 Nov. 2018) in Python (Python Software Foundation: Python language reference, version 3, <https://www.python.org/>, accessed 06 Nov. 2018). Morgan fingerprints of radius 2 (equivalent to ECFP4 \[[@bib69]\]) were computed for each compound. Compound similarity was calculated using the Tanimoto coefficient ([@bib93]) of the fingerprints using the scikit-learn library ([@bib59]). Based on the similarity matrix between all compound pairs, a dendrogram was obtained using the SciPy library (SciPy: Open Source Scientific Tools for Python, <http://www.scipy.org/>, accessed 06 Nov. 2018). The polar scatterplot was created using the matplotlib library (printed version) ([@bib32]) and plotly (interactive version) (Plotly Technologies Inc, Collaborative data science, Plotly, Montréal, QC, 2015). To identify duplicated molecules, the InChIKey ([@bib27]) was computed for each compound and all pairs of compounds were checked for identical InChIKeys. To create the compound network, the similarity matrix computed for the dendrogram was transformed into an adjacency matrix using a threshold value of 0.5; that is, compounds with a similarity value over 0.5 are connected with an edge. The network visualisation was created using Cytoscape ([@bib73]).

Statistical analysis {#s4-9}
--------------------

Statistical analyses were performed using GraphPad Prism version 7 for Mac, GraphPad Software, La Jolla California USA, [www.graphpad.com](http://www.graphpad.com). The Strictly Standardised Mean Difference (SSMD, *β*) ([@bib97]) for the dose-response measurements in [Figure 7D](#fig7){ref-type="fig"} was calculated using the formula:$$\beta = \ \frac{\mu_{1} - \mu_{2}}{\sqrt{\sigma_{1}^{2} + \sigma_{2}^{2}}}$$
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###### List of the 89 hit compounds that rescued the expression of *vcanb* in *adgrg6^tb233c^* mutants and were followed up by *mbp* counter screens.

The table includes the plate and well position of each compound, along with known activities and the raw data scores from nine *adgrg6^tb233c^* embryos in the *vcanb* assay (v1--v9), from six *adgrg6^tb233c^* embryos in the *mbp* assay (m1--m6) and from three *adgrg6^fr24^* embryos in the *fr24* (fr1--3) assay. Abbreviations: DE, dead embryo; ND, no data; S, Spectrum; T, Tocris. \*Deoxygedunin: ([@bib35]); Nobiletin: ([@bib16]); Angolensin (R): ([@bib88]); Sinensetin: ([@bib38]); Larixol acetate: ([@bib84]); Gedunin: ([@bib28]; [@bib79]).
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All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Table 1 and Figure 1-figure supplement 1, Figure 3, Figure 7 and Figure 7-figure supplements. Links to interactive files are given in the manuscript and in a supplementary file.
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Thank you for submitting your article \"Identification of compounds that rescue otic and myelination defects in the zebrafish *adgrg6 (gpr126*) mutant\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: David W Raible (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In \"Identification of compounds that rescue otic and myelination defects in the zebrafish *adgrg6 (gpr126*) mutant,\" Diamantopoulou, Baxendale et al., present the results of a set of screening and validation protocols that identify classes of compounds that rescue phenotypes associated with disruption to the adhesion gpcr *adgrg6*, aka *gpr126*. Disruption to *gpr126* in zebrafish leads to defects in inner ear morphogenesis and peripheral nerve myelination by Schwann cells. The availability of *gpr126* mutant alleles (missense and nonsense mutations) has allowed construction of a clever primary screen to identify regulators of mutant-related *vcanb* expression in the ear), and a secondary screen to identify compounds that do/don\'t also affect myelination. Extensive follow-up validation and categorisation has been carried out, culminating in the identification of compounds that may represent direct agonists of the aGPCR itself, which would be of great interest. In general the data are of a very high standard, the manuscript is well written, and all major claims are well substantiated by observations.

The reviewers and handling editor agreed that the major strength of this current work is as an excellent exemplar of how to execute and follow-up chemical genetic screens in zebrafish, rather than in the provision of specific insights into mechanisms of ear/glial cell biology. As such, we would encourage a revision in the Tools and Resources format. All reviewers and the handling editor agree that essential revisions outlined below should strengthen the manuscript and be achievable within the standard revision period.

Essential revisions:

Additional analyses are required related to the screen and follow-up analyses

1\) The network analysis is a nice way to categorize and display the different compounds and reveal possible commonalities. A good test of whether these commonalities are related to function would be to test additional related compounds not in the original panels. This is the principal request for new experimental data.

2\) The identification of 90 compounds out of 3000 (3%) seems rather high, suggesting that either the assays have a potentially high rate of false positive hits or there is the potential for nonspecific action revealed by the assays. Could the authors please comment on this?

Similarly, it would be nice if the authors provided a summary of the reproducibility of the *mbp* staining assay. These data are in Figure 5A, but the results appear more variable than the *vcanb* assay. Are there possible false-positives here?

3\) The dose-response functions provide a good measure of concentration dependent activity. It would have been nice if the controls were repeated with each dose-response function (they appear to be the same data across all graphs in Figure 7C), as these would give a better representation of the reliability of the assay. It would be good if the z-prime was calculated for this assay.

4\) The authors describe the similarities in results between 155 compounds found between the two libraries. It would be useful to report the statistical correlation between the two sets of scores as a measure of reliability.

A little more clarity in presentation/ writing is required in a few places throughout the manuscript.

5\) Following how compounds advanced through the testing funnel is a little hard to follow. It would be good if there were a way to easily represent this such as a flow chart or other graphic. For example it is not clear how the 91 compounds were identified by the secondary screen (Figure 4). Why were only some compounds advanced for retesting (227/297 compounds)? What criteria advanced them into secondary screening? I can\'t see an easy way to get 91 compounds from categories in Figure 4A (I get 88 compounds from retest categories A and B).

6\) The flow of paragraphs (subsection "Compounds that can rescue both inner ear and myelination defects") is not quite right in that the first paragraph talks about selecting two groups for further analysis and then the next paragraph also mentions compounds chosen for further study. This second announcement sounds independent of the first one. Perhaps in the second paragraph the authors could state, \"An additional selection...\" or a \'third group\'.

7\) The authors mention that the *fr24* allele encodes a highly truncated protein, but I am not sure I see any evidence of this, or in the previous cited paper. One might expect, instead, that this allele would lead to nonsense mediated mRNA decay, but even if this did not occur, it is rather hard to see how the predicted protein/ peptide fragment could be presented in a physiological manner. The authors should either remove, qualify, or amend this statement.

8\) It is not clear why the one screening concentration was selected? Can the authors explain, and discuss further in the context of screen design and execution.

9\) In Figure 8B the use of gray lines makes it difficult to visualize the gray circles.

10\) What is the significance of the yellow colors in the table shown in Figure 4A?

11\) For dose-response curves, were measurements done blinded?

12\) It is not clear what the two sets of graphs are in Figure 7A -- are these replicates?
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Author response

> Essential revisions:
>
> Additional analyses are required related to the screen and follow-up analyses
>
> 1\) The network analysis is a nice way to categorize and display the different compounds and reveal possible commonalities. A good test of whether these commonalities are related to function would be to test additional related compounds not in the original panels. This is the principal request for new experimental data.

We thank the reviewers for their suggestion and agree the network analysis is useful for the display of structural commonalities and as a basis for determining structure-function relationships. To test additional related compounds, we have taken the dihydropyridine network analysed in Figure 6 as a starting point and have selected four additional dihydropyridines that are structurally related to nifedipine, but which were not represented in the Spectrum or Tocris libraries. The new compounds tested are nilvadipine, nemadipine A, felodipine and lercanidipine, which are all drugs of the type used to treat hypertension and are available from Sigma. We have tested these additional compounds in *adgrg6* rescue assays; encouragingly, all four can also rescue the down-regulation of otic *vcanb* expression in *adgrg6^tb233c^* mutant embryos.

Nilvaldipine has a high structural similarity to nifedipine (Tanimoto similarity coefficient \>0.5), and we have modified the network in Figure 6B to show this (green circle). Nilvadipine was initially tested at 22.5 µM and showed a partial rescue of otic *vcanb* expression and a strong rescue of *mbp* expression around the posterior lateral line ganglion (new panels, Figure 6C vii, xiv). We also demonstrated a dose-dependent rescue of otic *vcanb* expression with higher concentrations of nilvadipine, with a reduction of expression to wild-type levels after treatment with 50.6 µM (new Figure 7---figure supplement 1).

The additional three new compounds showed a range of effects at 25 µM. Nemadipine A fully rescued otic *vcanb* expression, felodipine partially rescued and lercanidipine failed to rescue *vcanb* expression (Figure 7---figure supplement 1). We next tested if a higher drug concentration was effective for the latter two compounds. At 40 µM, felodipine still showed partial rescue of *vcanb* , but lercanidipine was able to rescue *vcanb* expression at 50 µM (Figure 7---figure supplement 1).

We also tested the Tocris compound (±)-Bay K 8644, which is included in the same network as nifedipine but did not score as a hit in the primary screen (25 µM). At a higher concentration (40 µM), we found that (±)-Bay K 8644 was now able to rescue otic *vcanb* expression (Figure 7---figure supplement 1). The testing of (±)-Bay K 8644 highlights how the network analysis can aid in prioritising compounds to test at alternative doses. These data are also relevant for our response to point 8 (see below).

We have described these new data in the Results (subsection "Compounds that can rescue both inner ear and myelination defects", last two paragraphs) and have also modified the Discussion (fourth and sixth paragraphs). See also modified Figure 6, and new Figure 7---figure supplement 1. Information on the source for the additional compounds is included in the Materials and methods (subsection "Compound storage, aliquoting and administration to embryos").

> 2\) The identification of 90 compounds out of 3000 (3%) seems rather high, suggesting that either the assays have a potentially high rate of false positive hits or there is the potential for nonspecific action revealed by the assays. Could the authors please comment on this?

This point also relates to point 5 asking for further explanation of the screening funnel for how compounds were selected. To address this, we have included a new graphical summary in Figure 4G, which we hope will clarify the screening results and outline our strategy to remove false positives and those compounds with non-specific action.

To summarise, the list of 91 hit compounds included two compounds that were present in both the Spectrum and the Tocris libraries, and therefore the total number of unique compounds was 89 out of a total of 3120 compounds (or 2965 excluding all duplicates). The counter screen for up-regulation of *mbp* expression also identified compounds that reduced transcription of both *vcanb* and *mbp*---potential false positives---and this reduced the number of verified hits with *vcanb* to 68 (2.3% of 2965). This counter screen also used two independent phenotypes (ear and myelination) to identify any hits that were not specific for the Adgrg6 pathway, and this reduced the number of hit compounds that could rescue both *vcanb* and *mbp* expression to 41 (1.4%). We further tested whether compounds were unable to rescue the strong allele as potential interactors with the Adgrg6 protein and identified 19 compounds (0.6%) in this final assay.

We therefore feel that the overall hit rate for Adgrg6 modulators of (1.4%) is not higher than we would expect in comparison to published phenotypic screens. Wiley, Redfield and Zon (2017) reviewed the percentage of hits identified from a variety of drug screens in zebrafish and our hit rate is well within the range seen in other phenotypic screens (Discussion, fifth paragraph). We have now cited this study in the Discussion (fifth paragraph). It should also be taken into account that the Tocris and Spectrum libraries include known bioactives and FDA-approved drugs, which are more likely to have activity in an in vivo screen than a completely novel synthetic compound library, where the hit rate would be expected to be lower. We expect the list of hits will include compounds, like colforsin and our control compound IBMX, acting downstream of Adgrg6 signalling by increasing cAMP levels, and we would expect there to be a number of compounds with similar activity in these two libraries.

We therefore prefer to retain the higher rate of false positives after the primary screen and then use the retests and counter screens to validate hits. The screening design could be made more robust by increasing the number of embryos screened or performing multiple repeats; however, in our experience, the time and financial cost of screening in duplicate or triplicate at the primary screen stage in order to identify fewer primary hits is not cost effective and would reduce the number of compounds screened overall. This is already discussed in the text (Discussion, fourth paragraph).

> Similarly, it would be nice if the authors provided a summary of the reproducibility of the mbp staining assay. These data are in Figure 5A, but the results appear more variable than the vcanb assay. Are there possible false-positives here?

The difference in *mbp* staining between wild-type and mutant embryos is highly reproducible, even when using the hypomorphic allele. Although expression in the PNS as a whole in the *adgrg6^tb233c^* mutant is variable, expression around the posterior lateral line ganglion is one of the few regions that is consistently absent, as discussed in the Results (subsection "Choice of markers for an in situ hybridisation-based screen: otic *vcanb* expression as a robust readout", last paragraph). To quantify this, and to illustrate the variability of *mbp* staining intensity around the posterior ganglion between individual wild-type embryos and *adgrg6* mutants, we have mounted individual embryos for imaging. In dorsally mounted embryos, it is possible to distinguish the peripheral *mbp* staining (decreased in mutants) from the CNS staining (unaffected in mutants). We have taken 10 *adgrg6^tb233c^* mutant embryos and 10 siblings from the same in situ hybridisation experiment and analysed the left and right posterior lateral line ganglion region from each embryo. After thresholding for colour using the HSB settings in Fiji we have plotted the percentage area of *mbp* staining. The results show a statistically significant reduction in staining area in mutant embryos. We have included these data in a new supplementary figure (Figure 1---figure supplement 1).

In the screen, some of the *mbp* staining results show variability between individual embryos treated with a given concentration of drug (Figure 5A), but as we are looking for up-regulation of gene expression in this assay, we would expect to have more false-negatives than false-positives at this stage. Note also that the individual mounting required for the quantitative analysis described above is not practicable for a large-scale primary screen.

> 3\) The dose-response functions provide a good measure of concentration dependent activity. It would have been nice if the controls were repeated with each dose-response function (they appear to be the same data across all graphs in Figure 7C), as these would give a better representation of the reliability of the assay.

To clarify, two different dose response assays were performed in separate 96-well plates and each plate included a set of controls. One plate screened increasing doses of FPL 64176 using an optimised assay window of 60-90 hpf and the second plate had increasing doses of nifedipine, tracazolate and cilnidipine using the time window of 60-110 hpf. There are therefore two sets of controls, one for the 60-90 hpf assay and another set for the 60-110 hpf assay. The experiment was repeated for both assay plates, and so the controls contain data points from two replicates. To make this information clearer we have rearranged this figure and legend so that the FPL 64176 data including controls is on one graph (Figure 7Di) and the other three compounds, with their controls, are on a second graph (Figure 7Dii).

> It would be good if the z-prime was calculated for this assay.

In general, z-prime scores are not suitable for in vivo phenotypic screens, such as this one, where the results are initially qualitative and then assigned to an arbitrary numerical scoring system, or where the sample size (*n*) is low. In order to have a significant z-prime score it is necessary to have well-separated distributions (large difference between the means, small standard deviations) between the positive and negative control.

Thus, instead of a z-prime score, we have used our quantitative data from the dose response assay to determine the SSMD (Strictly Standardised Mean Difference, β) for assessing assay quality. This method has been used in RNAi screens (Zhang, 2007). We used the data from Figure 7D (ear width measurements) and the SSMD formula for two independent groups,

β=μ1-μ2σ12+σ22

where µ~1~ is the mean ear width distance of the *adgrg6^tb233c^* mutants treated with DMSO (negative control) and µ~2~ is the mean ear width distance of the *adgrg6^tb233c^* mutants treated with IBMX (positive control), σ12is the variance of the negative control and σ22 is the variance of the positive control. This generated an SSMD score of 2.811 for the controls on the plate with nifedipine, cilnidipine and tracazolate, which demonstrates that this assay has a strong threshold for hit detection. Scores for the hit compounds, compared to the negative control, were also strong at the higher concentrations (nifedipine score 2.48 at 33.7 μM, cilnidipine score 4.19 at 22.5 μM and tracazolate score 3.5 at 22.5 μM). The controls for the FPL 64176 plate have a slightly lower score of 2.03 after a 24-hour treatment, compared with the 48-hour treatment on the other plate. FPL 64176 had a similar score of 2.04 at 6.7 μM. We have included all the scores in a modified Figure 7---figure supplement 2 and included the method in the statistics section of the Materials and methods (subsection "Statistical analysis") (see also revised Figure 7---figure supplement 2---source data 1).

> 4\) The authors describe the similarities in results between 155 compounds found between the two libraries. It would be useful to report the statistical correlation between the two sets of scores as a measure of reliability.

As mentioned in response to point 3, our primary assay scores are not suited to statistical correlation as they are not quantitative. We had analysed the duplicated compounds in detail and had already discussed the few differences we found in the text (subsection "Validation of the primary screen: retesting, comparison with control compounds and analysis of duplicates", third paragraph).

> A little more clarity in presentation/ writing is required in a few places throughout the manuscript.
>
> 5\) Following how compounds advanced through the testing funnel is a little hard to follow. It would be good if there were a way to easily represent this such as a flow chart or other graphic. For example it is not clear how the 91 compounds were identified by the secondary screen (Figure 4). Why were only some compounds advanced for retesting (227/297 compounds)? What criteria advanced them into secondary screening? I can\'t see an easy way to get 91 compounds from categories in Figure 4A (I get 88 compounds from retest categories A and B).

As discussed in response to point 2, we have now added further clarification of our screening funnel in the Materials and methods section and also made a new panel summarising the hit selection steps for Figure 4G. Briefly, from the primary screen, the list of hits included those in categories A--C. While we were interested in those that had the strongest rescue (A, B categories) we also wanted to determine how many compounds in category C would come through the retests as a hit. We therefore made up the cherry-pick 'hit' plates with extra compounds from the C category, although not all of category C compounds were retested. In addition, 10 compounds from the B category were not followed up due to a lack of compound availability in the cherry-pick plates---this is mentioned in the Materials and methods (subsection "Hit selection"). The table in the original Figure 4A confirmed that the majority of compounds from category C retested as category D (non-hit). However, we have taken the reviewers' comments on board and have removed this table and replaced it with a schematic of the hit selection process, which we hope will be clearer for the reader. We have moved some of the details of the screening process from the Results section to the Materials and methods section. The revised text can be found in the Results (subsection "Validation of the primary screen: retesting, comparison with control compounds and 286 analysis of duplicates", first paragraph) and Materials and methods (subsection "Hit selection"). See also the new Figure 4G.

> 6\) The flow of paragraphs (subsection "Compounds that can rescue both inner ear and myelination defects") is not quite right in that the first paragraph talks about selecting two groups for further analysis and then the next paragraph also mentions compounds chosen for further study. This second announcement sounds independent of the first one. Perhaps in the second paragraph the authors could state, \"An additional selection...\" or a \'third group\'.

We have now amended this section and moved the discussion of the heatmap to the previous section (subsection "Secondary screen for rescue of *mbp* expression, and identification of false positives", last paragraph). We have also clarified which of the selected compounds were from the two groups that correspond to the clusters in Figure 4D and Figure 5B and which were chosen separately and hopefully this is now clearer (subsection "Compounds that can rescue both inner ear and myelination defects").

> 7\) The authors mention that the fr24 allele encodes a highly truncated protein, but I am not sure I see any evidence of this, or in the previous cited paper. One might expect, instead, that this allele would lead to nonsense mediated mRNA decay, but even if this did not occur, it is rather hard to see how the predicted protein/ peptide fragment could be presented in a physiological manner. The authors should either remove, qualify, or amend this statement.

The reviewers are correct that we do not have any experimental evidence for the presence or absence of a truncated protein product in the *fr24* allele. We have been careful to explain this in the text (subsection "Choice of markers for an in situ hybridisation-based screen: otic *vcanb* expression as a robust readout", second paragraph) and have checked all other references in the manuscript to *fr24* to remove any ambiguity. As shown in Figure 1 and in our previous study (Geng et al., 2013), the *fr24* allele predicts a stop codon L463X which is within the extracellular domain of the protein, N-terminal to the hormone-binding domain and GAIN domain.

Although nonsense-mediated mRNA decay is a possibility, we have previously tested the presence of the *adgrg6* transcript in *adgrg6^fr24^* mutants by in situ hybridisation. In some regions expression is weaker, but expression in the swollen projections in the ear is strong (Geng et al., 2013). Given that some transcript is produced, it is possible that it is translated into protein. If the truncated N-terminal fragment (amino acids 1--462) is expressed as protein it would contain the signal peptide needed to export the peptide and also the CUB and PTX domains. We note that another truncating *adgrg6* allele, *st49*, is known to produce a slightly larger peptide, which retains the hormone binding domain and is biologically active in vivo, being able to restore radial sorting of axons in *adgrg6* mutants, so there is precedent for the production of truncated Adgrg6 peptides (Petersen et al., 2015). This is now discussed in the aforementioned paragraph.

However, the purpose of using the *fr24* allele in the current study is to distinguish between compounds that can activate downstream signalling of the Adgrg6 pathway (which are active whether the Adgrg6 protein is present or not) and those that potentially interact with the Adgrg6 protein (active in the weaker *adgrg6^tb233c^* allele; inactive in *fr24*). In the latter case, even if an N-terminal peptide is produced and is active in *fr24* mutants, the mutation predicts that the transmembrane domain necessary for G protein coupling to activate downstream signalling will be missing.

> 8\) It is not clear why the one screening concentration was selected? Can the authors explain, and discuss further in the context of screen design and execution.

The choice of compound concentration for screening is always a compromise between efficacy and toxicity. The concentration 25 μM was chosen empirically after analysing results from previous screens performed at both 10 μM (Baxendale et al., 2012) and 25 μM (pilot data from another screen, unpublished). These data suggested that the number of toxic compounds did not increase significantly at the higher concentration. 25 μM is within the range frequently used in zebrafish assays (Richter et al., 2017; Wiley et al., 2017). This is discussed in the fourth paragraph of the Discussion.

As highlighted in our response to point 1, the new Figure 7---figure supplement 1 now includes a panel of dihydropyridine compounds that were only partially active in the assay at 25 μM, but were active at higher concentrations of 40 or 50 μM. Lowering the concentration in the primary screen to 10 μM would have resulted in more hit compounds being missed, including nifedipine, based on our dose-response data in Figure 7B. Screening the compounds in duplicate with two different concentrations would have reduced the overall number of compounds we could screen, taking in to account the number of embryos available and the cost of other reagents. One potential compromise would be to take all the compounds that proved to be toxic at 25 μM and re-screen these cherry-picked compounds at a lower concentration.

> 9\) In Figure 8B the use of gray lines makes it difficult to visualize the gray circles.

The colour of the lines has been modified to make the network easier to visualise in Figures 6, 8 and Figure 7---figure supplement 1. The entire network is also available as an interactive version, where individual networks can be enlarged to aid visualisation.

> 10\) What is the significance of the yellow colors in the table shown in Figure 4A?

The yellow colours in the previous Figure 4A highlighted the categories with the highest numbers of hit compounds after retesting. However, after consideration of the reviewers' points 2 and 5 we have decided to remove this table and have replaced it with a schematic of the hit selection process that also still includes the numbers of compounds in each category at each stage (Figure 4G). See also our response to point 5 above.

> 11\) For dose-response curves, were measurements done blinded?

The ear measurements from the ear swelling dose response assays were not done blinded. In general, all plates were scored twice and by two different scorers. For the dose-response assay the reviewer refers to, the in situ hybridisation results for the *vcanb* staining were still available; we went back to the original plates and re-ordered them to do a retrospective blinded score. Here, we found the same overall trends as shown in Figure 7, with only a marginal difference between the intermediate dose scores, while the scores for the 'rescued' and 'not rescued' were the same in both cases. We have not amended the data in Figure 7B but have mentioned our method of scoring in the Materials and methods (subsection "Whole-mount in situ hybridisation analysis of gene expression").

> 12\) It is not clear what the two sets of graphs are in Figure 7A -- are these replicates?

The two sets of graphs record different measurements, but were scored on the same set of embryos. We have now made these two panels separate to make this clearer. The first panel (Figure 7A) is scored for the number of projections that have fused to form a pillar (i.e. morphological rescue of the inner ear defect, not just reduced *vcanb* expression). Figure 7B shows the overall score of the *vcanb* staining as defined in Figure 3A. We have modified the figure legend to make this clearer and explanation in the text is found in the first paragraph of the subsection "Nifedipine, cilnidipine, tracazolate hydrochloride and FPL 64176 rescue otic defects in *adgrg6^tb233c^*mutants in a dose-dependent manner".

[^1]: These authors contributed equally to this work.
